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Lymphatic vessels play a critical role in mounting a proper immune response by 
trafficking peripheral immune cells to draining lymph nodes.  Mast cells (MCs) are well 
known for type I hypersensitivity reactions but little is known about their secretory 
regulation in the lymphatic niche.  MCs, as innate sensor and effector cells, reside close to 
mesenteric lymphatic vessels (MLVs) and their activation and ability to release histamine 
influences the lymphatic microenvironment in a histamine-NF-B-dependent manner. 
Using surgically isolated rat mesenteric tissue segments, we tested the hypothesis that 
perilymphatic mesenteric MCs express histamine receptors (HR) that bind and respond to 
histamine that they release. Under various experimental conditions, including 
inflammatory stimulation by lipopolysaccharide (LPS), we measured histamine in 
mesenteric perilymphatic tissues, evaluated expression of histidine decarboxylase, the 
degree of MC degranulation, assessed the functional status of HRs in MCs, and evaluated 
the ability of histamine itself to induce MC activation. Finally, we evaluated the 
significance of MCs and histamine receptor 1 (H1R) and histamine receptor 2 (H2R) for 
MLV-directed trafficking of CD11b/c-positive cells during LPS-mediated acute tissue 
inflammation. Our data indicate the existence of a functionally active MC-histamine 
autocrine regulatory loop, the elements of which are crucially important for acute 
inflammation-induced trafficking of the CD11b/c-positive cells towards MLVs. Our data 
also suggest that this MC-histamine loop plays a key role in the innate and adaptive 




Current study along with previous evidence suggests the presence of an 
antagonistic relationship between H2R and H1R. Our demonstration of nuclear localization 
for H2R in different tissue types and cell lines in addition to the emerging evidence of G-
protein-coupled receptors as nuclear receptors led us to investigate the localization pattern 
for H2R in rat whole tissue segments as well as human lymphatic endothelial cells. We 
demonstrate histamine-dependent nuclear translocation kinetics of H2R as well as report 
that loss of function of H2R significantly attenuates such a translocation event. Altogether 
our results suggest that receptor-ligand complex formation is necessary for H2R nuclear 
translocation, which is known to be a key functional characteristic of type 1 nuclear 
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1.1. Mast Cells 
Since their first description by Paul Ehrlich in 1878 as ‘mastzellen’, mast cells 
(MCs) have been mostly viewed as effectors of allergy [1]. Investigations from the recent 
past have shown that nearly all vascularized organs, including the heart [2], lung [3] , 
kidney [4], intestines[5, 6], liver [7], brain side [8, 9] of the blood brain barrier, in addition 
to the interfaces of the host and the external environment, such as skin [10], have a 
prevalence of MCs. However, it has only been in the last two decades that MCs have 
gained significant attention for their involvement in several physiological and pathological 
processes [11]. MCs are hematopoietic in origin. After egression from the bone marrow, 
MC progenitors circulate in the blood, enter various tissues and develop into mature MCs 
under the influence of local growth factors, such as stem cell  factor  and interleukin‑3 (IL 
‑3). [12]. The cytoplasm of MCs carries secretory granules containing inflammatory 
mediators, such as histamine, heparin, and a number of cytokines among others. Upon 
activation, MCs release pre-stored granules into the surrounding tissue microenvironment 
initiating multiple physiological responses that are not just limited to allergy, but are also 
involved in vasodilation, neo-vascularization and defense against pathogen exposure [13] 
[14-16]. Interestingly, the recent findings on the close localization and density of MCs 
around blood and lymphatic vessels and their ability of regulated release of pre-stored as 
well as de novo vasoactive compounds expanded the scope of MC biology in the context of 
vascular biology [5, 17, 18]. Further, more recent studies also suggest MCs act as immune 
sentinels that can regulate the function of innate and adaptive immune cells, including
                                                              1 
2 
dendritic cells (DCs), macrophages, eosinophils, lymphocytes (T and B cells), and 
fibroblasts. In addition to that, they are also capable of presenting antigens by expressing 
major histocompatibility complex class II (MHC II) molecules [14, 19-21], which suggests 
their ability to induce adaptive immune response. 
1.1.1. Overview of MC Activation Mechanisms 
As innate sensor cells, MCs are equipped for early and rapid sensing of invading 
microorganisms such as bacteria, parasites, fungi, and viruses. The range and nature of MC 
responses to different stimuli can be influenced by intrinsic as well as micro-environmental 
factors, which can modulate the expression and functionality of MC surface receptors 
and/or signaling molecules that contribute to these responses [21, 22]. These pathogens 
display conserved molecular structures called pathogen-associated molecular patterns 
(PAMPs), which bind pattern recognition receptors (PRRs), such as Toll-like receptors 
(TLRs), on the MC surface. MCs express TLRs 1 to 7 and 9, nucleotide-binding and 
oligomerization domain-like (NOD-like) receptors (NLRs), and retinoic acid-inducible 
gene. Signaling through TLRs on the MC activates myeloid differentiation primary 
response 88 (MYD88) and MAL/TIRAP, which induces NF-κB translocation to the 
nucleus resulting in the transcriptional initiation of several cytokines. TLR4 can be 
activated by lipopolysaccharide (LPS), causing cytokine production as well as release of 
preformed granule constituents, whereas activation of TLR2 by peptidoglycan results in 
extensive degranulation [23, 24].  
The most extensively investigated pathway for MC activation is mediated through 




that binds to IgE, a β-chain that spans the membrane, and γ chains. LYN interacts and 
phosphorylates tyrosine in its ITAM (immunoreceptor tyrosine base activation motifs) on 
the β and γ chains of the FcϵRI, which further activates Syk tyrosine kinases and 
phosphorylates LAT1 and LAT2 (linkers for activation of T cells). Further, as a 
downstream cascade, phosphorylated phospholipase Cγ hydrolyzes phosphatidylinositol-
4,5-bisphosphate to make inositol-1,4,5-triphosphate and diacylglycerol causing calcium 
(Ca2+) mobilization from the endoplasmic reticulum. The release of Ca2+ from the ER 
leads to a stromal interaction molecule 1 (STIM1)-mediated opening of the store-operated 
Ca2+ channel ORAI1, leading to the influx of extracellular Ca2+. The influx of Ca2+ is 
accompanied by an additional mechanism that is mediated by transient potential Ca2+ 
channel 1. The increase in intracellular Ca2+ levels and the activation of protein kinase C 
triggers the degranulation machinery. Calcium release also activates NF-κB to translocate 
to the nucleus, which results in transcriptional initiation of several cytokines, such as IL-6, 
TNFα, and IL-13. However, activation of FcϵRI also activates Fyn (Src kinase), 
complementary to the Lyn signaling pathway, which can also modulate MC degranulation. 
Fyn activates phosphoinositide 3-kinase, as a downstream signaling cascade, and activates 
mammalian target of rapamycin (mTOR) in an Akt-dependent manner to induce MC 
chemotaxis and granule release.[16, 25-28] 
In addition to these well-known mechanisms, MCs can be activated by a wide array 
of stimuli such as neuropeptides, cytokines, growth factors, toxins, certain lectins, basic 
compounds, complement, immune complexes, certain drugs, as well as physical or 
mechanical stress. Recent investigations have shown that receptors for adenosine, 




are also involved in MC activation [29-32]. Activation of these receptors can also 
potentiate FcεRI-mediated activation. Another important aspect of regulation of MC 
granule release is MC desensitization. Although the mechanisms are not clearly 
understood, slow and persistent degranulation of MCs or repeated exposure to increasing 
doses of antigen can induce MC desensitization. MC desensitization can be used if a 
patient is allergic to a necessary drug or to prevent anaphylactic reactions to food [33].  
 
 




1.1.2. MCs as an effector cell in the interface of the lymphatic and immune system 
The density of MCs varies depending upon the species and the location. For 
example, the density is 7000-12,000 per mm
3
 in human skin and 20,000 per mm
3
 in 
intestines, whereas in the lungs, the density is 500-4000 per mm
3
 [34]. MCs also show a 
phenotypic heterogeneity (chymase and tryptase type) based on their residing 




chemokines, growth factors, proteases, and biogenic amines stored in granules. Beyond the 
role of MCs in hypersensitivity reactions, as an immune sentinel, MCs respond to a variety 
of immunogenic and non-immunogenic stimuli through the release of granules [35]. 
Release of granules can be broadly divided into two types: (1) degranulation characterized 
by rapid release of pre-synthesized granules [often seen in allergic reactions] and (2) de 
novo mediator release via a comparatively slow process that contributes to chronic 
responses during tissue remodeling, pathogen clearance and engagement with innate as 
well as adaptive immune cells.  
MCs, as innate effector cells, preferentially reside in the interface of the host and 
external environments [25, 36]. Activation of MCs modulates both adaptive and innate 
immune responses [35, 37]. For example, exposure to gram negative bacteria induces 
TLR4 signaling in MCs, which releases inflammatory mediators such as TNF-, IL-6, and 
IL-1beta, involved in chemotactic migration, upregulation of adhesion molecules and 
chemokine receptors in natural killer cells, eosinophils, and neutrophils (Table 1). MCs are 
also able to modulate adaptive immune responses. For example, release of histamine by 
MCs has been shown to regulate Type 1 T helper cell (Th1) and Th2 responses by 
inducing Th1- (IL-4, IL-10, IL-13) and Th2- (IFNg, IL-2) [38] specific cytokines through 








A recent study by Kambayashi et al. also suggests that MCs can induce expression 
of MHC II molecules, which can process and present antigens to CD4+ T cells as well as 
promote maturation of and directly transfer antigen to DCs [40]. The formation of MC-DC 
[41] or MC-T cell [42] immune synapses  can influence the capacity of MCs to recruit DCs 
or T cells to the site of an infection or injury, which endows MCs with the ability to 






Table 1. Major mast cell-secreted mediators in immune regulation 
Mediator Type of immune cell 
involved 
Function Reference 
TNF-alpha T naive, effector cells, 
macrophage 
Promote activation and 
proliferation of naive and 
effector T cells and suppress 







Recruitment and chemotaxis  [45-47] 
IL-12 Th1  Initiation of Th1 type response [48, 49] 
IL-6 Neutrophil, M2 
macrophage 
Regulation of inflammatory 
reactions, chemotaxis, T helper 
cell, macrophage polarization 
[50-52] 
CCL20 Dendritic cell Recruitment to inflammatory 
site 
[53, 54] 
IFN Gamma Th1  Th1 response, migration and 
proliferation. 
[55] 
Histamine  Th1, dendritic cell Cellular differentiation, 
chemotaxis 
[39, 56] 
IL-5 B cell  Terminal differentiation of 
activated B cell s 
[57, 58] 
IL-13 Fibroblast Facilitate Th2 type response [58] 
IL-16 CD4+ T cell T cell growth, chemoattraction [59] 
IL-8 ( CXCL8)  Neutrophil Chemotaxis [60] 
IL1-beta Dendritic cells and 
MCs  
T cell-independent dendritic 
cell activation, IL8 synthesis 
[61-63] 
MCP-1 (CCL2) Dendritic cells, memory 
T lymphocyte  
Recruitment [64, 65] 
RANTES/CCL5 Th2 Polarization towards Th2 
phenotype 
[66] 
Mast Cell Tryptase Neutrophils Recruitment [67] 
IL-4 Th2  
B cells 
Differentiation of naïve T cells 
to Th2 cells, migration, 
B cell maturation, B cell 
survival 
[58, 68, 69] 
TGF beta  iTreg, Th2,  
B cell  
Development of Tregs, 
B cell apoptosis and maturation 
[70, 71] 
IL-2 Th1, Treg Th1 and 2 differentiation, Treg 
survival and development 
 
[72, 73] 
IL-10 T follicular helper Downregulate Th1 cytokine [74] 
       TNF alpha: Tumor Necrosis Factor alpha, MCP: Macrophage Chemoattractant Protein  




MCs, as effector cells, sense inflammatory stimuli and orchestrate cellular influx 
into their residing tissue niche. Recent studies have shown that significant populations of 
MCs are closely localized near lymphatic vessels (LVs). Although the functional 
implication of such a localization pattern is not well investigated, it is reasonable to 
speculate that as the major sensory arm of the innate immune response, activated MCs can 
release a wide array of vascular and inflammatory mediators [75] that are able to diffuse to 
the adjacent LVs due to their proximity. These mediators can instantaneously interact with 
lymphatic endothelial cells (LECs) and promote expression of adhesion molecules such as 
integrins, which promote the recruitment of circulating leukocytes. Furthermore, 
chemotactic migration of leukocytes from adjacent lymph nodes as well as tissue 
parenchyma facilitates LV-directed immune cell trafficking, advancing the resolution of 
local inflammatory events. MC mediators can also influence overall lymphatic pumping 






Table 2.  Mast cell-derived mediators regulating the lymphatic vasculature 
MC mediator Effect on Lymphatics Signaling Axis Ref 








cell recruitment to LV 
P-Selectin [77, 81] 
TNF alpha Expression of adhesion 
molecules in vascular 
endothelial cells, 
lymphangiogenesis, 













activation of VEGF-C in 
LECs.  Adhesion molecule 










Kinin B2 Receptor [89, 90] 
IL-8 LEC growth, immune 
cell recruitment 
Adhesion molecule 
expression in ECs 
[91, 92] 
MC Tryptase Immune cell 
recruitment 
Matrix degradation 
CCL2, IL-8 expression in 
LECs 
 
[17, 93, 94] 
MC Chymase Matrix remodeling 
Neutrophil recruitment 
Conversion of Ang I to 






LV contractility Inhibition of lymphatic 
pumping in a PKA- 
dependent manner 
[96, 97] 
PDGF Lymphatic contractility 
Lymphangiogenesis 
Endothelium-dependent 
NO-mediated relaxation of 
lymphatic muscle through 
MAPK activation 
[98-100] 
FGF Lymphangiogenesis Activation of VEGF-C and 
VEGF-D 
[101, 102] 






Ang: angiotensin, IL: interleukin, CCL: chemokine ligand, MCP-1: monocyte 
chemoattractant protein, PDGF: platelet-derived growth factor, FGF: fibroblast growth 
factor, IFN gamma: interferon gamma, TGF beta: tumor growth factor beta VEGF: 
vascular endothelial growth factor, DC: dendritic cell, ECs, endothelial cells, LECs: 





1.2. Lymphatic vascular network and MCs in response to inflammation 
1.2.1. Overview of the lymphatic vascular network 
In the vertebrate circulatory system, the lymphatic vasculature represents a 
unidirectional transport system that moves extravasated interstitial fluid from the tissue 
parenchyma to the adjacent draining lymph node (see Fig.2). The lymphatic network is 
comprised of lymphatic nodes that are connected with afferent and efferent LVs. LVs can 
be subdivided into three types based on morphological structure: (1) Initial, (2) Pre-
collector, and (3) Collector. Initial lymphatics, having a single endothelial layer and a 
discontinuous basal lamina, also feature anchoring filaments in their structure, which help 
in the formation and entry of the lymph into the vessel. The initial lymphatic vasculature is 
involved in capillary fluid exchange and formation of lymph. Lymph further moves 
through pre-collectors, which mainly function as a conduit to transport the lymph content 
to the collecting lymphatics. The morphology of collecting LVs consists of a basement 
membrane, a lymphatic muscle layer (circular and longitudinal) and an endothelial layer 
(see Fig.2). The contractile functional unit of collecting LVs, also known as the 
lymphangion, exhibits spontaneous phasic and tonic contractions that help in lymph 
propulsion and move the fluid finally to the left subclavian vein via the thoracic duct. 
These lymphangions are separated by bicuspid valves that prevent backflow of lymph 
during the pumping activity [104-106]. Lymphatic pumping is dependent upon intrinsic 
factors, such as synthesis of LV-derived nitric oxide (NO) [107]. Extrinsic factors, such as 
forces caused by surrounding skeletal muscle activity, also influence lymphatic pumping, 




106]. Lymphatic muscle cells are unique in that they show characteristics of both striated 
and smooth muscle [108-110]. Evidence also suggests that the anatomical region and 
species specificity result in a wide variation in lymphatic pumping and flow [111-113]. 
Tight regulation of lymphatic muscle bioenergetics is crucial for steady state self-
contractile function and lymph propagation through lymphangions and subsequent lymph 
formation [114, 115]. However, recent studies on a model of metabolic syndrome suggest 
that modulation of lymphatic muscle cell bioenergetics can be affected by insulin 
resistance, which impacts lymph transport [115-117].  A mechanistic and detailed 
understanding of signaling mechanisms underlying lymphatic pumping is lacking. How 
lymphatic muscle cells respond and adapt during inflammation-mediated interstitial fluid 
volume increases as well as how inflammation affects transport efficiency of lymph by 










Figure 2. Lymphatic system architecture along with lymphatic niche. (1) Initial LVs; 
(2) Precollector LVs; (3) Perilymphatic antigen presenting cells; (4) Perilymphatic MCs; 
(5) Collecting LVs;  (5) Lymphatic valve in collecting LVs; (7) Degranulating MCs in 
response to inflammation; (8) Increased permeability of LV in response to inflammation; 
(9) Lymphatic endothelial cells; (10) Lymphatic muscle cells; (11) Inflammation-induced 









1.2.2. Role of lymphatic vessels and perilymphatic MCs in regulation of the 
inflammatory response  
Local inflammation causes pathological outcomes such as swelling with rapid 
influx of interstitial fluid accompanied by chemotactic migration of leukocytes into the 
affected area. Such pathophysiological change increases the overall tissue interstitial 
pressure gradient. This further pulls the anchoring filaments attached to the LV and leads 
to opening of lymphatic primary valves, which then helps to clear out accumulated 
antigens and noxious tissue debris from the inflamed site [118, 119]. In addition, this also 
helps to traffic immune cells from the affected site to the draining lymph nodes (see Fig.2). 
Lymph nodes, as a secondary lymphoid organ, are continuously perfused and presented 
with soluble foreign antigens by the lymph transported through afferent LVs. Continuous 
screening of lymph in the node is necessary for activation of node resident naïve antigen 
presenting cells and priming of naïve T and B cells in any given inflammatory stimuli. 
This underscores the importance of the regulation of continuous lymph flow by LVs and 
their machinery, such as lymphatic primary and secondary valves, lymphatic muscle cells 
and bidirectional interactions between tissue resident immune cells with LECs. Quite 
contrary to the traditional view of the lymphatic vasculature as a passive conduit for 
transporting macromolecules, emerging studies also suggest that an inflammation-induced 
microenvironment can upregulate the expression of several adhesion molecules, such as 
ICAM-1, VCAM-1, as well as chemokines, such as CCL21 and CX3CL1 in LECs. This 
can modulate enhanced trafficking and chemotaxis of antigen presenting cells such as DCs 
and macrophages from the adjacent lymph node through efferent LVs to the affected site, 




chemokine scavenging receptor D6 expressed by LECs can selectively regulate the 
interaction between mature and immature DCs, which helps in the cellular trafficking and 
removal of inflammatory chemokines. However, the expression of this D6 receptor is 
dependent upon molecules such as IL-6 and interferon gamma present in the inflammatory 
microenvironment [121]. In addition, inflammation can induce expansion of the lymphatic 
network through initiation of lymphangiogenic programs in a VEGF-C-dependent manner 
along with molecules such as TNF alpha, FGF, and IL-6 secreted by LECs as well as 
immune cells closely associated with LVs (such as perilymphatic MCs and tissue resident 
or migratory macrophages). Although considerable progress has been made in 
understanding the basic mechanisms of lymphangiogenic programs, the role of other 
regulatory factors such as exosomes [122] and damage associated molecular patterns 
(DAMPs) [123] released by LECs or other perilymphatic tissue or immune cells in the 
regulation of inflammation-associated lymphangiogenesis is yet to be elucidated.  
MCs are the major innate effector cell type localized close to LVs [5, 17] and are 
able to release a number of inflammatory and vasoactive mediators (see Table 1 and Table 
2). These unique features allow MCs to be strongly relevant and a key player in the 
regulation of lymphatic immuno-physiology. Inflammation-induced activation of MCs and 
subsequent release of granules not only modulate lymphatic endothelial, muscle and 
immune cell interaction in the tissue microenvironment but also vascular properties as a 
whole (such as permeability, vessel contractile efficiency, lymph generation and pumping 
as well as vascular remodeling) [124].  In addition, MCs release molecules such as VEGF, 




lymphatic capillary density and LV-associated immune cell invasion in the inflammation 
affected site [125].  
However, it is still unclear whether lymphangiogenesis contributes to the 
inflammatory pathology or acts in the resolution and repair of the damaged tissue site but, 
overall, evidence suggests that chronic exposure to an inflammatory environment has a 
negative regulatory effect on lymphatic muscle as well as endothelial cells. Further, 
activation and subsequent regulated release of granules from MCs exhibits a context-
dependent effect. Overall, inflammation-induced dysfunction of LVs causes significant 
stasis of lymphatic fluid transport as well as diminished trafficking of lymphocytes to the 
draining lymph node, causing overall immune suppression. The resultant altered immune 
environment leads to clinical manifestations, such as lymphedema, local fibrosis and 
secondary bacterial infections. These pathologies are strongly associated with diseases, 
such as secondary lymphedema, that are often seen in surgical intervention of lymph nodes 
to limit cancer progression or in lymphatic filariasis or lipedema cases [126].  
1.2.3. Role of the lymphatic vasculature in peripheral tolerance and implication of 
perilymphatic MCs 
LVs and capillaries are intimately involved in interactions with antigen presenting 
cells, their trafficking from peripheral tissue parenchyma to the adjacent lymph nodes and 
further immune cell transmigration from the lymphatic capillary or lumen of the collecting 
vessels to the draining lymph node or the inflamed site. However, in this process, the 
‘immune-lymphatic’ communication depends on the expression of adhesion molecules, 
several chemokines ligands (e.g., CCL19 and CCL21), vasoactive mediators and their 




CLEVER-1 [127] expressed by the LECs. Accumulating evidence in recent years suggests 
that the lymphatic vasculature actively participates in peripheral tolerance. LECs are 
directly exposed to lymph, which is enriched with self-antigens, and they have been shown 
to scavenge the self-antigens from lymph as well as to express MHC I and II molecules, 
but not co-stimulatory molecules [128, 129].  This enables LECs to cross present 
peripheral tissue antigens to self-reactive T cells independent of autoimmune regulator 
(Aire) [129]. Furthermore, the expression of the inhibitory ligand PDL1 by LECs induces 
T cell clonal depletion and helps to maintain peripheral tolerance in homeostasis [130, 
131]. However, whether LECs are able to express other immuno-regulatory molecules for 
the induction of CD4 T cell tolerance, how LECs acquire exogenous antigens and cross 
present, whether exosomes play a role in this context, what mechanisms are associated 
with distinct differences in LECs from different anatomical locations and their role in 
autoimmune diseases are still questions that remain to be answered.  
MCs predominantly serve as immune sentinels and mediate dynamic MC-T cell 
[132] and MC-DC [133] interactions through formation of an immune synapse, which 
underscores a potential possibility of intercellular crosstalk with LECs given their 
anatomical proximity to lymphatic capillary or vessels. Furthermore, evidence suggests 
that MCs participate with T regulatory cells in the maintenance of graft tolerance [134]; 
however, degranulation of MCs can suppress T regulatory cell function, which essentially 
breaks down peripheral tolerance [135]. Altogether, the MC-LEC axis is still an under 
investigated area that holds a promising potential in the context of therapeutic intervention 





1.3. Histamine, a major mast cell mediator in lymphatic contractile physiology  
A previous study by Gasheva et al. showed that endothelial NO blockade, either by 
Nω-methyl-L-arginine acetate (L-NMMA) or by Nω-nitro-L-arginine methyl ester 
hydrochloride (L-NAME), was not able to completely eliminate all endothelium-dependent 
relaxation induced by increased imposed flow in rat mesenteric lymphatic vessels (MLVs) 
[136]. The existence of this phenomenon is supported by the presence of a mechanism that 
is shear-dependent, but NO-independent, in rat MLVs, where endothelial-derived 
histamine can play a role as a relaxing factor [137]. Furthermore, the presence of 
significant populations of MCs serving as the major extrinsic source of histamine in the 
LV niche, a MC degranulation-dependent effect on lymphatic contractility [124] and 
finally concentration-dependent negative chronotropic effects of histamine in ex vivo 
isolated  LVs [76] support the significance of histamine as an important player in 
lymphatic contractile physiology. However, the precise molecular mechanism by which 
histamine exerts its chronotropic effect in lymphatic muscle contractility is still not clear. 
Previous studies have shown that LVs express histamine receptors (HRs) [138] and studies 
from the past in porcine coronary arteries suggest that activation of HRs can increase Ca+2 
influx by Ca+2 channel-dependent release of intracellular Ca+2 [139]. In addition, 
histamine can induce endothelial contraction [140] as well as disrupt endothelial barrier 
function in a RhoA-ROCK-dependent formation of focal adherent junctions causing an 
increase in vascular permeability [78]. One of the predominant characteristics of a 
collecting LV is pacemaker activity and self-contractility, which often depend upon the bi-
directional communication between lymphatic muscle and endothelial cells. Such myo-




tight junction proteins, such as ZO-1, play a crucial regulatory role. There is a lack of in 
depth studies in the present literature in the context lymphatic physiology; however, 
previous studies suggest that regulation of histamine secretion can impact LEC ZO-1 





2. HISTAMINE-MEDIATED AUTOCRINE SIGNALING IN MESENTERIC 
PERILYMPHATIC MAST CELLS 
2.1. Introduction 
 MCs, as granulocytic effector cells [143], are known for their significant 
contribution to IgE-dependent anaphylactic reactions, infections, asthma and various 
allergies [144]. Additionally, there is an emerging body of evidence that suggests that MCs 
are also closely associated with several cardiovascular pathologies, including myocardial 
infarction and atherosclerosis [2, 145-147]. MCs can produce, store, and release, upon 
activation, numerous bio-active and, in particular, vasoactive mediators that continuously 
modulate the surrounding tissues, including blood and lymphatic vessels, by which MCs 
are usually located in high density [5, 143, 148-162]. Histamine, a major MC mediator, 
interacts with cells through binding with its four G protein-coupled receptor subtypes - 
histamine receptors 1-4 (H1R-H4R) [163] - expressed in various tissue types, including 
MLVs [164-169]. Previous studies have shown that histamine can specifically activate NF-
B signaling, which, in turn, modulates inflammatory reactions through transcriptional 
initiation of numerous pro-inflammatory cascades [170, 171]. Recently we demonstrated 
that, in the mesentery, MC activation and release of histamine is triggered during acute as 
well as during aging-associated chronic inflammation in perilymphatic tissues [172]. MCs 
act as cellular elements controlling recruitment/activation of immune cells in perilymphatic 
tissues as well as lymphatic contractility and permeability [78, 172, 173] through release of 




Our previous studies revealed that aging-associated activation of MCs is able to 
maintain NF-B phosphorylation in a histamine-dependent manner [172]. We considered 
these findings as indicative of persistent release of histamine in aged perilymphatic tissues. 
At the same time, the literature indicates that skin [174], bone marrow [175] and ocular 
[176, 177] MCs express various subtypes of HRs. Therefore, we hypothesized that 
mesenteric MCs can express HRs at the same time those receptors can bind with their 
released histamine, which can facilitate and maintain MC activation and histamine 
secretion in an autocrine manner.  To test this hypothesis, we used an established 
experimental protocol of surgical isolation of rat mesenteric tissue segments including 
MLVs along with surrounding perilymphatic tissues [5, 172, 178]. We measured local 
levels of histamine in mesenteric perilymphatic tissues, evaluated the contribution of MCs 
and the subtypes of MC-expressed HRs to histamine release upon acute inflammatory 
stimulation. Under different experimental conditions, we evaluated expression of histidine 
decarboxylase (HDC), the histamine-producing enzyme in MCs, and intensity of MC 
degranulation. We confirmed the presence of H1R and H2R in perilymphatic MCs, 
including their involvement in acute inflammation-induced NF-κB phosphorylation, tested 
the ability of histamine itself to induce activation of perilymphatic MCs. Finally, we 
evaluated the importance of H1R and H2R in MC degranulation and MLV-directed 







2.2. Material and Methods 
2.2.1. Reagents and antibodies   
Lipopolysaccharide from E.coli (LPS) (catalog # L3129), toluidine blue (catalog # 
198161), ruthenium red (catalog # R2751), cromolyn sodium (catalog # C0399), 
compound 48/80 (catalog # C2313), pyralimine maleate  (catalog # P5514), cimetidine 
(catalog # C4522), thioperamide maleate (catalog # T123), histamine dihydrochloride 
(catalog # H7250), and Triton X100  (catalog # T8787) were obtained from Sigma-
Aldrich, St Louis, MO. Phosphate buffered saline (PBS) 10x (catalog # 6505) was 
obtained from EMD Chemicals, Gibbstown, NJ, and normal goat serum (catalog # 005-
000-001) was obtained from Jackson ImmunoResearch Laboratories, West Grove, PA. The 
histamine ELISA kit was obtained from Enzo Life Sciences, Farmingdale, NY (catalog # 
ENZ-KIT140-0001). Antibodies were obtained from the following sources: Phospho-NF-
κB p65 from Cell Signaling Technology, Boston, MA (catalog # 3033S); histidine 
decarboxylase from Abcam, Boston, MA (catalog # ab37291), histamine receptor 1 
(catalog # AHR-001) and histamine receptor 2 (catalog # AHR-002) from Almone Labs, 
Jerusalem, Israel; histamine receptor 2 from Novus Biologicals, CO (catalog # NLS1175); 
and CD11b/c from Biolegend, San Diego, CA (catalog # 201801). Avidin 488 conjugate 
(catalog # A21370), avidin Texas Red conjugate (catalog # A820), Alexa Fluor 647 goat 
anti-rabbit H+L (catalog # A-21245), Alexa Fluor 488 goat anti-mouse IgG1 (catalog # A-
21121), Alexa Fluor 647 goat anti-mouse H+L (catalog # A-21236), and ProLong Glass 
Antifade Mountant with NucBlue Stain (catalog # P36985) were from ThermoFisher 




ImmunoResearch; and EverFluor FL histamine (catalog# 7148) from Setarah Biotech, 
Eugene, OR.  
2.2.2. Animal procedure and tissue surgical dissection 
All animal procedures for the current studies were reviewed and approved by the 
Texas A&M Institutional Animal Care and Use Committee. For the current study, male 
Sprague Dawley rats with an average body weight 200±50 g were used. Rats were 
euthanized by overdose of isoflurane followed by thoracotomy – i.e., the ventral chest wall 
was opened by deep lateral incision. Immediately post mortem the sternum and half of the 
adjacent ribs were excised and the inferior vena cava was cut to drain blood. The 
abdominal cavity was opened by midline abdominal incision, the two ends of the gut 
included in the area to be excised were sutured before excision to avoid fecal 
contamination of the preparation, and the root of the mesentery was clamped to minimize 
further bleeding. The excised gut with attached mesentery was rinsed three times in 1x 
PBS. For perilymphatic tissue dissection, the gut was pinned down in a Sylgard
®
-coated 
10-mm Petri dish submersed in cold physiological salt solution (in mM: 145.0 NaCl, 4.7 
KCl, 2.0 CaCl2, 1.2 MgSO4, 1.2 NaH2PO4, 5.0 dextrose, 2.0 sodium pyruvate, 0.02 
EDTA, 3.0 MOPS) with the pH adjusted to 7.36. The whole mesentery from an individual 
animal was rapidly excised and, using a dissecting microscope, was separated into 
segments that included MLVs and perilymphatic tissues, but did not include large 
segmental mesenteric arteries or veins. As MCs are sensitive to mechanical stress and 






2.2.3. Measurement of acute inflammation-induced histamine release 
The whole mesentery from an individual animal was dissected into nine segments 
and further treatments were conducted as described below. For these experimental 
treatments we used the following substances: LPS (10 µg /ml) to initiate an acute 
inflammatory response in perilymphatic tissue segments; cromolyn sodium (25 µM) to 
stabilize MCs; pyrilamine maleate (1 µM) as an H1 receptor antagonist, cimetidine (100 
µM) as an H2 receptor antagonist, and thioperamide maleate (1 µM) as an H3 and H4 
receptor antagonist. The following treatment combinations were utilized: (1) Control,  (2) 
LPS treatment, (3) Cromolyn + LPS treatment, (4) H1 blocker + H2 blocker + LPS 
treatment,  (5) H2 blocker + H3/4 blocker + LPS treatment,  (6) H1 blocker + H3/4 blocker 
+ LPS treatment,   (7) Cromolyn + H1 blocker + H2 blocker + LPS treatment, (8) 
Cromolyn + H2 blocker + H3/4 blocker + LPS treatment, and  (9) Cromolyn + H1 blocker 
+ H3/4 Blocker + LPS treatment.   
A summary of incubation times for each treatment regimen is as follows: 
1. Control: 5 hours incubation in PSS. 
2. LPS treatment: 2 hours incubation in PSS, then 3 hours incubation in PSS with 
LPS.           
 3. Cromolyn + LPS treatment: 2 hours incubation in PSS with cromolyn, then 3 




4. H2 blocker + H3/4 blocker + LPS treatment:  2 hours incubation in PSS with H2 
and H3/4 blockers, then 3 hours incubation in PSS with H2 and H3/4 blockers along with 
LPS.           
 5. H1 blocker + H3/4 blocker + LPS treatment:  2 hours incubation in PSS with H1 
and H3/4 blockers, then 3 hours incubation in PSS with H1 and H3/4 blockers along with 
LPS.           
 6. H1 blocker + H2 blocker + LPS treatment:  2 hours incubation in PSS with H1 
and H2 blockers, then 3 hours incubation in PSS with H1 and H2 blockers along with LPS. 
7. Cromolyn + H2 blocker + H3/4 blocker + LPS treatment: 2 hours incubation in 
PSS with cromolyn, H2 and H3/4 blockers, then 3 hours incubation in PSS with LPS along 
with cromolyn, H2 and H3/4 blockers. 
8. Cromolyn + H1 blocker + H3/4 blocker + LPS treatment: 2 hours incubation in 
PSS with cromolyn, H1 and H3/4 blockers, then 3 hours incubation in PSS with LPS along 
with cromolyn, H1 and H3/4 blockers. 
9. Cromolyn +H1 blocker + H2 blocker + LPS treatment: 2 hours incubation in 
PSS with cromolyn, H1 and H2 blockers, then 3 hours incubation in PSS with LPS along 
with cromolyn and H1 and H2 blockers. 
After treatments, the tissue segments were quickly transferred to pre-weighed 1.5 ml 
Eppendorf tubes, snap frozen in liquid nitrogen and stored at -80ºC for future analyses. The 
individual weights of empty tubes and tubes with tissue samples were collected to 
normalize data to tissue weight. We processed full sets of nine treated segments from each 




Histamine concentration was measured according to the manufacturer’s protocol using 
histamine ELISA kit plates. Samples were analyzed in duplicate (with some selected 
randomly to be analyzed in triplicate). The following equations were used to evaluate the 
roles of certain histamine receptors in acute inflammation-induced histamine release: 
 Equation 1: Total specific histamine receptor-mediated (H1R, 2, or 3/4) histamine 
release in perilymphatic tissues = Histamine concentration in tissue segments treated with 
LPS (treatment group 2) - tissue histamine concentration in treatment groups 4, 5, or 6. 
(Example 1: Contribution of H1R in LPS-induced histamine secretion by 
perilymphatic tissues = Histamine concentration in tissue segments treated with LPS 
(treatment group 2) - histamine concentration in treatment group 4.    
 Equation 2: Specific histamine receptor-mediated histamine release in 
perilymphatic tissues not mediated by MC degranulation = Histamine concentration in 
tissue segments treated with LPS (treatment group 2) – histamine concentration of 
treatment groups 7, 8, or 9.       
 (Example 2: Contribution of H1R in LPS-induced histamine secretion by 
perilymphatic tissues not mediated by MC degranulation = Histamine concentration in 
tissue segments treated with LPS (treatment group 2) - histamine concentration in the 
treatment group 7.)        
 Equation 3: Specific histamine receptor-mediated histamine release in 
perilymphatic tissues mediated only by HRs in MCs = Total specific histamine receptor-
mediated (HR 1, 2, or 3/4) histamine release in perilymphatic tissues (equation 1 
corresponding to receptor subtype) - specific histamine receptor-mediated histamine 




receptor subtype).         
 All duplicate (or triplicate) measures were averaged within each segment, then 
averages from similar types of treatments were used for calculations within each rat and, 
lastly, these measures were averaged for the 6 rats used. 
2.2.4. STRING analysis to explore interaction between HRs and HDC 
Evaluation of the possible network of protein-protein interactions between HRs 
1/2/3/4 and HDC was carried out using STRING, a precomputed database (version 10.5) 
(https://string-db.org/). Our queries were for each type of HR, assessing the interacting 
protein network associated with HDC in our model organism, Rattus norvegicus. In the 
database settings, we chose the first shell of interactions (where the most relevant ten 
interacting proteins are shown). No second shell of interactions was chosen to avoid 
unrelated interactions. Scale of interaction scores is considered according to the following: 
highest confidence - 0.900; high confidence - 0.700; medium confidence - 0.400; low 
confidence - 0.105 [179, 180].  
2.2.5. Evaluation of HDC expression in mesenteric perilymphatic MCs  
Exteriorized mesenteric tissue segments from 4 rats were dissected as described in 
section 2.2.2. and incubated as described in 2.2.3. The following treatment groups were 
implemented in segments from each rat: untreated control – incubated for 5 hours in PBS, 
48/80 (positive control for MC degranulation) – 2 hour control incubation and 3 hour 
treatment with compound 48/80 (10 g/ml), LPS – 2 hour control incubation and 3 hour 
treatment with LPS, Crmln+LPS – 2 hour pre-treatment with cromolyn sodium before and 




and H2R antagonists before and along with 3 hour treatment with LPS. Tissue segments 
were fixed with 4% paraformaldehyde, rinsed three times for 20 min each with PBS and 
blocked with blocking buffer (5% goat serum, 0.1% Triton X100 in PBS) for 60 min at 
room temperature. Incubation with HDC primary antibody (1:100 dilution in blocking 
buffer) was done overnight at 4ºC. The following day segments were washed and 
incubated with Alexa Fluor 647 goat anti-rabbit H+L (1:200 dilution) together with 
staining for MCs using Alexa Fluor 488-conjugated avidin (1:200) for one hour at room 
temperature. The segments were then washed three times for 20 min each with PBS and 
mounted on slides. Antifade reagent was applied before placing the coverslip. Images were 
acquired using the same acquisition settings for all slides (here and below) on an Olympus 
Fluoview 300 confocal microscope with a 60x water objective with 1.15 numerical 
aperture and step size of 0.5 m. For mean fluorescence intensity (MFI) measurements, the 
corresponding signals were quantified with the NIH ImageJ program. First, images were 
converted to an 8-bit grey scale, regions of interest (ROIs) with MCs were marked on the 
488 nm channel, and the MFI of the 647 nm channel was measured on the marked ROIs. 
Fluorescence signals of HDC in individual MCs from at least four ROIs in each segment 
were averaged within each treated segment and then averaged between corresponding 
segments obtained from all animals. All obtained values were normalized to the untreated 
control within each animal to average between different animals [181]. Statistical 
differences were determined by ANOVA, regression analysis and Student’s t-test (JMP 
software version 9.0.2. for Windows, SAS Institute Inc., Cary, NC) and considered 
significant at p < 0.05. (A similar approach for statistical analysis was used in other groups 




2.2.6. Histamine receptors 1 and 2 in LPS induced MC degranulation 
Exteriorized mesenteric tissue segments from 4 rats were dissected as described in 
section 2.2.2. and incubated as described in 2.2.3. The following treatment groups were 
implemented in segments from each rat (two segments for each treatment for each animal): 
untreated control incubated for 5 hours in PBS, LPS – 2 hour control incubation and 3 hour 
treatment with LPS, H1B+LPS – 2 hour pre-treatment with H1R antagonist before and 
during 3 hour treatment with LPS, and H2B+LPS – 2 hour pre-treatment with H2R 
antagonist before and during 3 hour treatment with LPS. Tissue segments were fixed with 
4% paraformaldehyde and rinsed three times for 20 min each with PBS. To study the MC 
degranulation pattern, one segment from each treatment group was stained with toluidine 
blue and another one with the Alexa Fluor 488-conjugated avidin, as previously described 
[5]. These two types of staining allowed us to avoid bias during quantification of results. 
Randomly selected ROIs in toluidine blue-stained segments were imaged using an 
Olympus CKX41 microscope under bright field at 20x magnification. Alexa Fluor 488-
conjugated avidin-stained segments were imaged using an Olympus Fluoview 300 
confocal microscope at 40x magnification at the appropriate excitation/emission 
wavelengths. The pattern of degranulation was further classified based on methodology 
described by Carlos et al. [182]. We assigned degranulation patterns in the perilymphatic 
MCs to three main categories: (1) Absent - characterized by all of the following: a) cellular 
membrane of the MC is continuous, thus MCs retain their typical round/oval shape; b) no 
visible granule remnants in the periphery surrounding MCs; c) granule density inside MCs 
is high and toluidine blue or avidin staining intensities are fairly dense.  (2) Partial - 




discontinuous with partial loss of typical MC round/oval shape, cells often increased in 
size;  b) visible granule remnants are seen in periphery surrounding MCs; c) MC granule 
density under both types of staining methods is visibly less than in non-degranulated cells  
(3) Extensive - characterized by presence of all of the following: a) complete loss of 
cellular membrane and typical round/oval shape of MCs; b) MCs look like conglomeration 
of degranulated fragments; c) significant decrease in MC granule density.  Based on these 
characteristics, all MCs from each image were classified and further quantified by both 
toluidine blue and avidin staining. Distribution of the categories of MC degranulation was 
determined in at least five ROIs in each segment and data from at least five ROIs were 
averaged within each treated segment, followed by averaging between corresponding 
segments obtained from all animals. Quantitative analysis was performed separately in 
toluidine blue- and avidin-stained segments. 
2.2.7. Analysis of the presence and functionality of histamine receptors 1 and 2 in 
perilymphatic MCs 
2.2.7.A. Analysis of H1R and H2R expression in MCs  
Dissected tissues segments were treated for immunohistochemical labeling as 
described in 2.2.5., while permeabilization with 0.1% Triton X100 in PBS was performed 
for 15 min before blocking. Blocking was performed with 5% goat serum in PBS. Primary 
antibodies specific for H1R and H2R were used at a 1:50 dilution. Similar to HDC 
expression studies (2.2.5.), Alexa Fluor 647 goat anti-rabbit H+L secondary antibody 
(1:200 dilution) was used together with staining for MCs with an Alexa Fluor 488-




Antifade Mountant with NucBlue Stain to define localization of nuclei in the MCs. Images 
were acquired using the same acquisition settings on an Olympus Fluoview 300 confocal 
microscope with a 60x water objective with 1.15 numerical aperture and step size of 0.5 
m. We visually evaluated the presence and cellular localization of H1R and H2R in MCs 
in at least four ROIs from each of 3 mesenteric tissue segments obtained from 3 animals. 
2.2.7. B. Fluorescently labeled histamine binding assay 
Tissue segments dissected from 3 animals (8 segments per animal) were divided 
into 4 treatment groups (2 segments per group) and incubated for 2 hours as following:  
untreated control incubated in PBS; H1B – treatment with H1R antagonist; H2B – 
treatment with H2R antagonist; and H1H2B – treatment with a combination of HR 1 and 2 
antagonists. Tissue segments were then incubated with 10µM fluorescently-tagged 
histamine (EverFluor FL histamine) along with Texas Red-conjugated avidin (dilution 
1:200) for 60 min at 4°C with gentle shaking. Proper caution was taken to avoid direct 
exposure to light during this and the following procedures. After 60 min of incubation, 
unbound dyes were rinsed by washing 3 times for 10 min each in PBS at 4°C. Tissue 
segments were then placed on slides and images were taken using a 40x water immersion 
objective on an Olympus Fluoview 300 confocal microscope under appropriate 
excitation/emission wavelengths. The image analysis approach was similar to that 
described in 2.2.5. 
2.2.8. Experiments with histamine-induced MC activation  
Tissue segments dissected from 3 animals (10 segments per animal) were divided 




– incubated for 5 hours in PSS, 48/80 (positive control for MC degranulation) – 2 hour 
control incubation and 3 hour treatment with compound 48/80 (10 g/ml), Histamine – 2 
hour control incubation and 3 hour treatment with histamine dihydrochloride (10µM), 
Crmln+His – 2 hour pre-treatment with cromolyn sodium before and during the 3 hour 
treatment with histamine dihydrochloride, H1H2B+His – 2 hour pre-treatment with H1R 
and H2R antagonists before and during the 3-hour treatment with histamine 
dihydrochloride. After incubation, to further identify actively degranulating MCs, the 
tissue segments were incubated in 24-well plates for 30 min at 37°C with ruthenium red 
(RR) (0.00125%) in PSS, as described previously [5]. Segments were then briefly washed 
with warm PSS 3 times, mounted on slides and imaged using an Olympus CKX41 
fluorescent microscope under brightfield using a 10x objective as implemented before [5]. 
Actively degranulating MCs were identified by RR uptake, which creates red/pink 
coloration of MCs [5]. Images of five ROIs from each segment were taken. To identify all 
existing MCs, all tissue segments were fixed and stained with toluidine blue (TB) (which 
stains all MCs regardless of their activation status) as described earlier [5]. The images of 
the same ROIs in all segments were re-taken using an Olympus CKX41 microscope with 
the same settings as described above. Further, from each image, all RR-labeled and TB-
labeled MCs were counted. The percentage of actively degranulating MCs was calculated 
as: (Mean of RR-labeled MCs in a given image of a treated segment / mean of TB-labeled 
MCs in the images of the same treated segment)*100%. All data were averaged within a 
single segment, then within similarly treated segments from one rat, and then within 




2.2.9. Measurements of expression of phosphorylated NF-B in mesenteric 
perilymphatic tissue segments 
Tissue segments dissected from 4 animals (6 segments per animal) were divided 
into 6 treatment groups and treated as following: untreated control – incubated for 5 hours 
in PBS; LPS – 2 hour control incubation and 3 hour treatment with LPS; Crmln+LPS – 2 
hour pre-treatment with cromolyn sodium before and during the 3 hour treatment with 
LPS; H1B+LPS – 2 hour pre-treatment with H1R antagonist before and during the 3 hour 
treatment with LPS; H2B+LPS – 2 hour pre-treatment with H2R antagonist before and 
during the 3 hour treatment with LPS; and H3/4B+LPS – 2 hour pre-treatment with HR 3/4 
antagonist before and during the 3 hour treatment with LPS. After treatments, all segments 
were processed, imaged and analyzed identically as previously described in detail by us 
[172]. At least four ROIs were analyzed in each segment with averaging of data as 
described in 2.2.8. 
2.2.10. Expression of H1R and H2R in perilymphatic tissue segments and CD11b/c 
positive cells 
Tissue segments dissected from 3 animals (2 segments per animal) were incubated 
for 5 hours in PBS as performed for untreated controls. Subsequently, the tissue segments 
were further processed for immunofluorescence staining as described in 2.2.5 Primary 
antibodies specific for H1R, H2R and CD11b/c were used at a 1:50 dilution. For H1R and 
H2R staining, the secondary antibodies used were Alexa Fluor 647-conjugated goat anti-
rabbit H+L, and for CD 11b/c staining Alexa Fluor 488-conjugated goat anti-mouse IgG1 




Olympus Fluoview 300 confocal microscope with a 60x water objective with 1.15 
numerical aperture and appropriate negative controls. Visual evaluation of cellular co-
localization of H1R, H2R and CD11b/c signals was performed in at least four ROIs in each 
mesenteric tissue segment. 
2.2.11. Evaluation of interactions between MCs, H1R and H2R, and CD11b/c-positive 
cells in perilymphatic mesenteric tissues 
2.2.11.A. Quantification of direct contact of MCs with CD11b/c-positive cells in 
perilymphatic mesenteric tissues 
Tissue segments dissected from 4 animals (6 segments per animal) were divided 
into 3 treatment groups (2 segments per group) and treated as following: untreated control 
– incubated for 5 hours in PSS, 48/80 – 2 hour control incubation and 3 hour treatment 
with compound 48/80 (10 g/ml), LPS – 2 hour control incubation and 3 hour treatment 
with LPS. After treatments, tissue segments were further processed for 
immunofluorescence staining as described in 2.2.5  The dilution for the CD11b/c antibody 
was 1:50. Secondary antibody used for CD11b/c staining was Alexa Fluor 647-conjugated 
goat anti-mouse H+L and Texas Red-conjugated avidin (both at a 1:200 dilution). Imaging 
was performed on an Olympus Fluoview 300 confocal microscope with a 40x water 
objective. At least five images were captured in each segment. Quantification of MC-
CD11b/c-positive cell contacts was performed using ImageJ software by visually assessing 
the number of MCs that appeared in direct contact with CD11b/c-positive cells using 
previously published criteria [183]. The obtained values from different treatment groups 




2.2.11.B. Analysis of CD11b/c-positive cells trafficking towards MLVs 
Tissue segments dissected from 4 animals (6 segments per animal) were divided 
into six treatment groups and treated as following: untreated control –  incubated for 5 
hours in PBS, 48/80 (positive control for MC degranulation) – 2 hour control incubation 
and 3 hour treatment with compound 48/80, LPS – 2 hour control incubation and 3 hour 
treatment with LPS, Crmln+LPS – 2 hours pre-treatment with cromolyn sodium before and 
during 3 hour treatment with LPS, H1B+LPS – 2 hour pre-treatment with H1R antagonist 
before and during 3 hour treatment with LPS, H2B+LPS – 2 hour pre-treatment with H2R 
antagonist before and during 3 hour treatment with LPS. After treatments, tissue segments 
were further processed for immunofluorescence staining as described in 2.2.5., but solely 
with CD11b/c antibodies as described in 2.2.5.a. Images were collected at 20x 
magnification using an Olympus Fluoview 300 confocal microscope. ROIs were purposely 
selected with MLVs centered in the field of view. MLVs were identified by their typical 
morphology with intraluminal valves between adjacent lymphangions. MLVs were imaged 
with 1 m z-axis steps in the direction from the intestinal wall to the root of the mesentery 
to have at least 3 ROIs in each segment. Image reconstruction and orthogonal viewing of 
the image stacks were performed using ImageJ software. CD11b/c-positive cells were 
counted in close proximity to MLVs using a previously employed method [162]. The 
obtained values from different treatment groups were normalized to the untreated control 






2.3. Results  
2.3.1. Role of histamine receptors on mesenteric perilymphatic MCs in acute 
inflammation-induced histamine release  
Histamine is ubiquitously synthesized in a number of physiological organ systems, 
including the cardiovascular, gastrointestinal, as well as immune systems. However, the 
majority of tissue histamine is synthesized and secreted by the resident MCs [143], 
including mesenteric perilymphatic MCs, which were the subject of this study. Fig. 3 
demonstrates that a significant proportion of mesenteric MCs are located near MLVs (Fig. 
3. A.1, bright field image.) MLVs are identified by their intraluminal valves (Fig 3. A.1, 3-
4). MCs stain with avidin conjugate (Fig. 3. A.2) and with toluidine blue (Fig 3. A.3-4). 






Figure 3. Localization of MCs near MLVS. There is a significant number of mesenteric 
MCs near the MLV [A.1 bright field, MLV identified by its intraluminal valve, MCs 




In the first set of experiments, we determined the role of MCs in perilymphatic 
histamine synthesis/secretion in response to LPS-induced acute inflammation. For these 
experiments as well as for other experimental sets, we dissected and used perilymphatic 
tissue segments (as shown in Fig. 4, panels A.1-3). Segments were treated with or without 
LPS following treatment by cromolyn to stabilize the MCs (i.e., prevent degranulation). 




that LPS-induced acute inflammation significantly increased tissue histamine 
concentration by 30.2±9.8% (75.4±12.4 ng/g wet tissue) compared to control (59.6±10.1 
ng/g wet tissue). Stabilization of MCs by cromolyn blocked this LPS-induced tissue 
histamine elevation (57.7±9.4 ng/g wet tissue). The effects of different treatments were 
normalized to the untreated control group. To delineate the role of specific HR subtypes in 
acute inflammation-induced histamine synthesis/secretion by the perilymphatic MCs, in 
the next set of experiments perilymphatic tissue segments were treated with a combination 
of HR antagonists in the presence of LPS with or without cromolyn sodium pre-treatment, 
which specifically stabilizes MCs [162]. Using the equations described in the Methods 
section, we evaluated the functional role of specific HRs in acute inflammation-induced 
histamine synthesis/secretion in the mesenteric perilymphatic tissues. We found that 
activation of only MC H1 receptors by LPS treatment induced a 47.1±12.6% increase in 
tissue histamine levels compared to untreated control, whereas the activation of only MC 
H2 receptors diminished tissue histamine levels to 36.9±13.7% compared to untreated 
control. Finally, activation of only MC H3/H4 receptors by LPS caused negligible changes 
in tissue histamine levels (non-significant 96.5±6.7% compared to untreated control). The 
results of histamine concentration determinations in perilymphatic tissues described above 
and presented in Fig. 4.A.4 led us to consider the experimental design of the next parts of 
the study. An increase of tissue histamine due to acute inflammatory stimulation by LPS 
was predominantly a MC-dependent process (i.e. histamine increases in response to LPS 
treatment were eliminated after MC stabilization by cromolyn). This could be indicative of 
an LPS-induced increase in both synthesis and release of histamine by MCs. Experiments 




following. When only the H1R is kept active in MCs, we found that the LPS-induced 
increase of tissue histamine was statistically similar to histamine levels observed with LPS 
treatment when all HRs were active. Taking into account the 5-hour duration of 
experiments, we believe MC H1 receptors contributed to the acute inflammation-induced 
increase in both synthesis and release of histamine. However, activation of only H2 
receptors in MCs in the presence of LPS induced a decrease in tissue histamine levels 
compared to control. Considering that we believe that MC H2 receptors may be involved 
in acute inflammation-induced release of histamine by MCs, they apparently do not 
stimulate its synthesis or do not stimulate it quickly enough (within 5 hours) to replenish it 
in MCs. The non-significant fluctuations of tissue histamine near its control level in the 
presence of only H3/4 receptors active in MCs indicate they are not involved in acute 
inflammation-induced increases of histamine synthesis and subsequent release by MCs. 
Together, these findings demonstrate the functional importance of H1 and H2 receptors in 
MCs for acute inflammation-induced release of histamine (i.e., they are crucial for this 
process), but the role of H3/4 receptors was at best minor in these settings. Another 
possible explanation for the absence of changes in tissue histamine concentration in 
conditions where H3/4 receptors were kept active would be that H3/4 receptors potentially 
may prevent increases in both synthesis and release of histamine by MCs. However, based 
on the present result, we believe that if this role of H3/4 receptors in MCs exists, its 
functional importance during acute inflammation is negligible. In conclusion (including 
H3/4Rs, second column from the left on Fig. 4.A.4), LPS induced a significant increase in 
tissue histamine concentration, which is comparable to the histamine level when only 




active, the cumulative result of LPS action will be the same, independent of the functional 
status of the H3/4 receptors (active or blocked). Therefore, we conclude that H3/4 
receptors in MCs are not functionally significant for acute inflammation-induced release of 
histamine in perilymphatic mesenteric tissues. 
 
 
Figure 4. Estimation of HR-mediated histamine release by perilymphatic segments. 
Illustration of the surgical isolation of mesenteric perilymphatic tissue segments (A.2) 
from intestinal loops (A.1) A.3 shows a live single MLV from the isolated segment.  A.4. 
Effects of various experimental treatments on histamine concentration in mesenteric 
perilymphatic tissues (untreated control, treatment with LPS, Crmln+LPS-pre-treatment 
with cromolyn sodium before and during treatment with LPS, MC H1R active+LPS – pre-
treatment with HR 2-4 antagonists before and during treatment with LPS, MC H2R active 
+LPS – pre-treatment with HR 1 and 3/4 antagonists before and during treatment with 
LPS, MC H3R&H4R+LPS – pre-treatment with H1R and H2R antagonists before and 
during treatment with LPS (n=6, normalized to untreated control, * indicates significant 




To further confirm this conclusion, we utilized the web-based STRING platform, 
version 10.5 (https://string-db.org/) to evaluate predicted protein-protein associations 
between subtypes of histamine receptors and the histamine-producing enzyme histidine 
decarboxylase (HDC) with an accuracy of more than 80% [184]. Based on our query, both 
H1 and H2 receptors in the Rattus novergicus database showed strong predicted nodal 
interactions with HDC with confidence intervals H1R-HDC: 0.706, H2R-HDC: 0.730, 
which are considered to be high (Fig 5, A-B). However, H3R did not show any nodal 
interaction with HDC and H4R showed a considerably weaker nodal interaction with HDC 
(HR4-HDC: 0.400). The results of this analysis reinforced our conclusions that only H1R 
and H2R in MCs are functionally important for acute inflammation-induced increases in 
histamine synthesis and release by MCs.  
 
 
Figure 5.  Illustration of web-based STRING analysis in H1R and H2R.  Predicted 
protein-protein interactions between subtypes of histamine receptors and the histamine-




In the next set of experiments, we evaluated the importance of HRs 1 and 2 for 
acute inflammation-induced upregulation of HDC in perilymphatic mesenteric MCs (Fig. 6 
A-B). Fig. 6, Panel A demonstrates that LPS significantly increased HDC expression (~4-
fold compared to untreated control). Treatment with compound 48/80, known for its ability 
to activate MCs (i.e., a positive control) [5], induced upregulation of HDC expression as 
expected. However, treatment of segments with the MC stabilizer cromolyn or HR1 and 
HR2 antagonists significantly eliminated LPS-induced upregulation of HDC expression in 
perilymphatic MCs (no significant differences in HDC expression compared to untreated 
control) (Fig. 6A). Representative images of MCs under these experimental settings are 
presented in Fig. 6B. Cumulatively, these data led us to conclude that acute inflammation-
induced activation of MC HRs 1 or 2 (or both) is necessary for activation of HDC in 






Figure 6. Effects of experimental treatments on expression of MC HDC expression in 
mesenteric perilymphatic MCs.   Various treatments were studied (untreated control, 
48/80 – treatment with compound 48/80, LPS – treatment with LPS, Crmln+LPS –
treatment with cromolyn sodium before and during treatment with LPS, similarly 
H1/H2B+LPS) A: Mean fluorescence intensity (MFI) of HDC measured in mesenteric 
perilymphatic MCs after various experimental treatments. (n=4, normalized to untreated 
control, * indicates significant differences [p < 0.05] between certain treatments). B: 
Representative images of mesenteric segments containing mast cells (MCs, stained by 
Alexa Fluor 488-conjugated avidin, in green), additionally labeled for HDC (in red) and 







2.3.2 Role of histamine receptors 1 and 2 in acute inflammation-induced MC 
degranulation 
MCs are involved in regulation of physiological functions through release of 
numerous mediators pre-stored in granules. Although this complex process is not clearly 
understood, the release of MC granules, in general, is broadly divided into two categories: 
(1) Extensive MC degranulation, also known as anaphylactic granule release, where 
significant portions of pre-stored granules are released in a short period of time; and (2) 
Constitutive exocytosis or secretion where de novo synthesized or pre-stored mediators are 
released in a much slower fashion (i.e., partial MC degranulation) [154, 182, 185]. 
Therefore, in the next set of experiments, we delineated the role of HRs 1 and 2 in this 
effector function of MCs upon acute inflammatory stimulation by LPS. We stained 
mesenteric perilymphatic MCs with avidin and toluidine blue and further evaluated their 
granule release pattern under control conditions, after LPS treatment and after LPS 
treatment on segments pre-treated with H1R antagonist or H2R antagonist. Based on 
literature data [154, 182, 185] and our own experience, we evaluated MCs based on 
whether MC degranulation was absent, partial or extensive under the different 
experimental conditions. Fig. 7 A-F demonstrates representative images of all variants of 
MC degranulation status. We used two separate staining methods, avidin and toluidine 
blue staining, in segments from each animal and analyzed all images associated with each 









Figure 7. Representative images of all variants of MC degranulation status. MCs 
stained with avidin (A,B,C) or toluidine blue (D,E,F). A,D: no degranulation, B,E: partial 




The cumulative results of this set of experiments are presented in Fig. 8 A.1-2 with 
calculations made with both images of avidin-stained MCs (panel A.1) and images of 
toluidine blue-stained MCs (panel A.2). Fig. 8.B.1-8 show representative images of MCs 




of degranulation: partial degranulation: extensive degranulation (referred to below as 
A:P:E ratio) was 93:7:0 and 94:6:0 for avidin and for toluidine blue-stained MCs, 
respectively. Treatment with LPS resulted in profound activation of the mesenteric 
perilymphatic MCs – average A:P:E ratios were 39:50:11 and 47:45:8, respectively. Pre-
treatment with an H1R antagonist before and during treatment with LPS shifted these 
ratios (73:27:0 and 74:25:1), which is indicative of predominantly partial MC 
degranulation. Pre-treatment with an H2R antagonist before and during the LPS treatment 
also altered these ratios (50:35:15 and 50:36:14), demonstrating increased appearance of 
extensive MC degranulation and fewer MCs with absent degranulation. Overall, the LPS-
induced degranulation of MCs is attenuated when H1R is blocked but activated MCs are 
more extensively degranulated when H2R is blocked. In summary, these data confirm that 
HRs 1 and 2 differentially regulate an acute inflammation-induced degranulation of 









Figure 8. Quantitative analysis of MC degranulation under different experimental 
conditions. Various treatments (untreated control, LPS – treatment with LPS, pre-
treatment with H1R antagonist before and during treatment with LPS (H1B+LPS), and pre-
treatment with H2R antagonist before and during treatment with LPS (H2B+LPS) were 
studied (n=4, average mean values presented). A.1 represents the quantification by avidin. 
A.2 represents quantification by toluidine blue.  C. Representative images of MCs under 
each experimental condition stained with either avidin or toluidine blue (B1-B7). Scale 






2.3.3. Presence and functionality of histamine receptors 1 and 2 in perilymphatic MCs 
Based on data presented in 2.3.2 and to further demonstrate that mesenteric 
perilymphatic MCs express both H1R and H2R, we investigated their expression patterns 
using fluorescent labeling of MCs. MCs were identified by MC-specific staining with 
avidin-Alexa Fluor 488 conjugate [5, 17]. We found that H1R and H2R exist in all 
observed MCs (representative images with overlap of HR signal and MC-specific avidin 
signal presented in Fig. 9, A.1-A.2.). The H1R staining pattern was diffuse over MCs 
suggesting both cytoplasmic and membrane localization of H1 receptors. The H2R staining 
pattern was concentrated in the periphery of MCs, suggesting a membrane localization of 
H2 receptors; however, interestingly, we also observed some nuclear staining by DAPI 
consistently overlapped with the H2R signal in MCs (Fig. 9, A.2). Further detailed studies 
will be necessary to link HRs 1 and 2 with particular cellular compartments in MCs. We 
also observed (representative images presented in Fig. 9, A.1-A.2.) that cells in 
perilymphatic mesenteric tissues other than perilymphatic MCs also exhibit positive 





Figure 9. Representative images of mesenteric perilymphatic tissue segments showing 
expression of H1R and H2R. Positive staining in red for H1R (A.1) and H2R (A.2) 
together with the labeling of the same segment by Alexa Fluor 488-conjugated avidin (in 




To confirm the functional expression  of both HRs 1 and 2 in the mesenteric 
perilymphatic MCs, we performed receptor-ligand interaction studies using fluorescently-
labelled histamine [39, 174, 186, 187]. Fig 10, A.1 demonstrates the typical pattern of 
binding interactions between externally-introduced (to MCs) histamine and MCs. Fig 10, 
panels A.2-4 demonstrate that pre-incubation with H1R and H2R antagonists blocked 
binding of fluorescently labelled histamine to MC receptors. For quantification of these 
results, we measured the intensity of fluorescently-labeled histamine in the MCs. We 




fluorescence intensity (MFI) of histamine to 41.9±9.8%, pre-treatment with H2R 
antagonist diminished MFI of histamine to 25.4±4.9%, while combined pre-treatment with 
both HR 1 and 2 antagonists reduced this MFI to 21.7±2.7%, all relative to control (Fig. 
10). Thus, these data confirmed the presence of HRs 1 and 2 in the perilymphatic MCs and 





Figure 10. Fluorescently labelled histamine binding interaction with receptors. Mean 
fluorescence intensity (MFI) of fluorescently-labeled histamine measured in mesenteric 
perilymphatic MCs after various experimental treatments: H1B – pretreatment with H1R 
antagonist, H2B – pretreatment with H2R antagonist, H1H2B – pretreatment with both 
H1R and H2R antagonists, (n=3, normalized to untreated control, * indicates significant 
differences (p < 0.05) between treatment groups and control) ( A1-A4). B: Representative 
images of mesenteric segments containing mast cells (MC, stained by Texas Red-
conjugated avidin, in red) bound with fluorescently-labeled histamine (FLU-His, in green), 





2.3.4. Histamine itself is able to induce activation of perilymphatic MCs  
We examined whether treatment with histamine itself is sufficient to activate 
mesenteric perilymphatic MCs and leads to release of granules pre-stored in MCs. To 
study activation and granule release in live MCs, tissue segments were treated with 
ruthenium red (RR), which has previously been shown to be taken up only by MCs 
releasing granules (i.e., activated MCs) and, specifically, by MC granules that are already 
extracellularly located [5, 188-190]. RR staining allowed us to specifically identify 
actively degranulating MCs in mesenteric perilymphatic tissue segments under various 
experimental treatments. To identify the total number of MCs in the same segments for 
normalization purposes, we used toluidine blue (TB) staining as employed before [5].  
Panels A.1-A.10 of Fig. 11 demonstrate pairs (not in the exactly the same segments) of 
representative images of each experimental condition where MCs have been stained with 
both RR and TB. Fig. 11B presents a summary of the experimental results. In agreement 
with previously published data [5, 172], under control conditions we observed a low level 
of MC activation (4.7±0.9% of total MCs), whereas compound 48/80, used as a positive 
control, induced a profound activation of MCs (71.0±8.4% of total MCs). Subsequently, 
we found that histamine introduced externally to MCs was able to induce significant 
activation (44.8±4.8% of total MCs). At the same time, pre-treatment with antagonists of 
HRs 1 and 2 or stabilization of MCs by cromolyn significantly decreased the MC-
activating effect of external histamine to levels not different from control conditions 
(19.3±1.1% and 10.4±2.6% of total MCs, correspondingly). Inserts in Fig. 11 (A1-A10) 




release. Treatment with compound 48/80 induced a loss of the typical MC structure with a 
discontinuous periphery of the cells and released granules (A.3 and A.4). This pattern was 
similar when perilymphatic mesenteric segments were treated with histamine (A.5 and 
A.6). These effects were significantly attenuated when tissue segments were pre-treated 
with a MC stabilizer (A.7 and A.8) or with HR 1 and 2 antagonists (A.9 and A.10). These 
data confirm that extracellular histamine itself is able to induce MC activation in an H1R- 













Figure 11. Histamine itself is able to induce activation of perilymphatic MCs.  A. 
Representative images of MCs stained with both ruthenium red (R.Red) and toluidine blue (T.Blue) 
under different experimental conditions [untreated control - A.1 and A.2., 48/80 – treatment with 
compound 48/80 (A.3 and A.4), treatment with histamine (A.5 and A.6), pre-treatment by cromolyn 
before and during treatment with histamine (Crmln+His) (A.7 and A.8), pre-treatment by H1R or  H2R 
antagonists before and during treatment with histamine (H1B+His, H2B+His) (A.9 and A.10)].  The 
inserts from each picture demonstrate the detailed structure of the MCs under the experimental 
conditions. Scale bars represent 200 m.  B.  Quantitative analysis of mesenteric perilymphatic MC 
activation under various experimental conditions (n=3, * indicates significant differences (p < 0.05) 




Cumulatively, the results presented above and in Fig. 11 confirmed following: 
1. Mesenteric perilymphatic MCs provide an increase in the synthesis/secretion of 




not HRs 3 and 4, are involved into regulating this response, including expression of HDC, 
the histamine-producing enzyme, within MCs.       
 2. HRs 1 and 2 differentially regulate an acute inflammation-induced degranulation 
of mesenteric perilymphatic MCs and thus tissue histamine levels. 
3. HRs 1 and 2 are present on the perilymphatic MCs and are able to effectively 
bind with extracellular histamine. 
4. Extracellular histamine itself is able to induce MC activation in an H1R- and 
H2R-dependent manner.         
 Taken together these data indicate that, once activated and degranulated by acute 
inflammation, MCs serve as a major source of extracellular histamine. This histamine, 
released by MCs, is able to bind with MC HRs 1 and 2 and, as such, maintain or re-initiate 
further MC degranulation. We propose that this set of events forms a MC-histamine 














2.3.5. MC-histamine autocrine loop: functional implications in mesenteric 
perilymphatic tissue compartments  
Recently we established that MCs activate NF-κB signaling [191] via a histamine-
dependent process [172]. Activated NF-κB signaling through numerous regulatory 
pathways controls lymphatic contractile and barrier functions as well as immune cell 
trafficking towards/through collecting lymphatic vessels [172]. In this study, we evaluated 
the role of specific HRs in acute inflammation-induced NF-κB activation. Fig. 13 shows 
the representative images and results of quantitative analysis of obtained data. Both 
compound 48/80 (positive control) and LPS were able to significantly increase NF-κB 
phosphorylation (144.4±8.4% and 166.9±6.0%, respectively, compared to control). MC 
stabilization by cromolyn as well as blockade of either H1R or H2R was able to eliminate 
activation of NF-κB induced by acute LPS treatment (92.0±4.6%, 87.4±5.5% and 
104.7±4.7%, respectively, compared to control conditions). At the same time, blockade of 
HRs 3 and 4 was able to significantly diminish, but not eliminate, the LPS-induced NF-κB 





Figure 13. Role of HRs in LPS-induced NF-κB phosphorylation. A. Expression of 
phosphorylated NF-κB in mesenteric perilymphatic tissue segments under different 
experimental treatments [(untreated control, LPS-treated, Crmln+LPS – pre-treatment with 
cromolyn sodium before and during treatment with LPS, H1B+LPS – pre-treatment with 
H1R antagonist before and during treatment with LPS; H2B+LPS – pre-treatment with 
H2R antagonist before and during treatment with LPS; H3/4B+LPS – pre-treatment with 
HR3/4 antagonist before and during treatment with LPS; (n=4, normalized to untreated 
control, * indicates significant differences (p < 0.05) between certain treatments)]. Panels 
B: Representative images of mesenteric perilymphatic tissue segments following various 




 These studies suggest the effects of acute inflammation-induced MC/histamine-
dependent upregulation of NF-κB phosphorylation in whole mesenteric perilymphatic 
tissues, but include activation of other (than MCs) cell types that may express all types of 
HRs. Even with major roles for HRs 1 and 2 in these events, it is clear that not only MCs 
but numerous other cell types express these receptors (representative images demonstrated 
on Fig. 14 A-B). However, the roles of these effector cells in MC/histamine-dependent 





Figure 14. Expression of H1 and H2R in perilymphatic tissue. Numerous cell types beyond 
MCs express HRs 1 and 2 in mesenteric perilymphatic tissues. Representative images showing 
immunohistochemical staining for HRs 1 or 2 (shown in red) and cell nuclei (DAPI, shown in blue) 




MCs, as sentinels of innate immunity, have previously been reported to be 
necessary players orchestrating DC trafficking towards sites of infection [192]. Recently, 
we demonstrated that mobilization and recruitment of MHC class II positive cells 
(MHCII+) and eosinophils requires activation of MCs [162]. We linked these events as 
well as the reported LPS-induced modulation of neutrophil recruitment and macrophage 
polarization on lymphatic vessels [193] to the activation of the MC/histamine/NF-B axis 
in perilymphatic tissues [172]. In particular, these conclusions were based on consideration 
of the well-known role of NF-B in the activation of CD11b-positive cells [194]. In this 
study, we evaluated the possibility of direct influence of MCs and histamine on the 
function of CD11b/c-positive cells in perilymphatic mesenteric tissues. In experiments 
utilizing fluorescent labeling of HRs 1 (Fig 15A) and 2 (Fig 15B) in perilymphatic 
mesenteric tissues, we found that almost all CD11b/c-positive cells expressed both HRs 1 






Figure 15. Expression of H1R and H2R in CD11b/c positive cells. Almost all CD11b/c-
positive cells (shown in green, together with DAPI staining shown in blue) express both 
HRs 1 (A) and 2 (B) (shown in red, together with DAPI staining shown in blue) - 




In addition, we found that activation of MCs significantly increased the number of 
MCs that were physically associated (i.e., make contact) with CD11b/c-positive cells 
(representative images shown in Fig. 16.A). Both compound 48/80 and LPS were able to 
increase the fraction of mesenteric perilymphatic MCs that were found in direct contact 
with CD11b/c-positive cells (56.9±3.5% and 56.0±4.4%, respectively, compared to 






Figure 16. MC activation-induced MC-CD11b/c direct interaction in perilymphatic 
tissue. Activation of MCs significantly increases the number of MCs that appear 
physically associated with CD11b/c-positive cells. A: Results of quantitative analysis (n=4, 
* indicates significant differences (p < 0.05) between certain treatments: untreated control, 
48/80 – treatment with compound 48/80, LPS – treatment with LPS). B: Representative 
images (fluorescent labeling similar to 5B). Scale bars represent 50 m. 
 
 
Finally, we evaluated the importance of MC activation and HRs 1 and 2 for 
trafficking of CD11b/c-positive cells towards MLVs, where the MCs are present in greater 
density than in the rest of the mesenteric tissue [5, 162]. Using the analysis implemented 
before for evaluation of density of MHCII+ cells and eosinophils in mesenteric 
perilymphatic tissues [162], we found the following: MC activation initiated a ~2-fold 




224.9±21.4% for compound 48/80- and for LPS-initiated MC activation, respectively, 
normalized to control conditions [Fig. 17.A (representative images) and 17.B]). MC 
stabilization with cromolyn sodium as well the action of H1R or H2R antagonists 
eliminated acute inflammation/LPS-induced increases in the number of CD11b/c-positive 
cells near MLVs (129.7±6.9%, 136.4±8.5% and 127.4±2.5%, respectively, normalized to 
control conditions [Fig. 17.A (representative images) and 17.B]). 
 
 
Figure 17. Role of MC activation and histamine signaling in MLV-directed migration 
of CD11b/c+ cells.  A. Representative images of trafficking of CD11b/c-positive cells (shown in 
green) towards MLVs under different experimental treatments (untreated control, 48/80 – treatment 
with compound 48/80, LPS – treatment with LPS, Crmln+LPS – pre-treatment with cromolyn sodium 
before and during treatment with LPS, H1B+LPS – pre-treatment with H1R antagonist before and 
during treatment with LPS; H2B+LPS – pre-treatment with H2R antagonist before and during treatment 
with LPS). Scale bar represents 100 m.  B. Results of quantitative analysis [n=4, * indicates significant 






Cumulatively, our results indicate that activation of MCs and functional HRs 1 and 
2 play a crucial role in MLV-directed trafficking of CD11b/c-positive cells during acute 
tissue inflammation. Schematic presentation of the involvement of perilymphatic MCs in 
the regulation of CD11b/c-positive cell trafficking towards MLVs in response to LPS-






Figure 18. Schematic of involvement of perilymphatic MCs in regulation of MLV-






2.4. Discussion  
One of the vital functions of lymphatic vessels is to provide the space to sense 
antigens present in the interstitium and that enter the lymph [195] as well as to provide the 
traffic route for immune cells from tissues to the draining lymph nodes for mounting a 
proper immune response [196-198]. MCs are known as tissue resident cells, involved in 
both sensing of changes in tissue microenvironment and modulating the innate and 
adaptive immune responses in the body [199-202]. Our previous studies have 
demonstrated that aging-associated basal activation (i.e. chronic under resting conditions) 
of perilymphatic MCs limits their response to acute inflammation [5]. Our follow-up study 
clearly demonstrated that recruitment/activation of MHCII+ cells and eosinophils in 
perilymphatic tissues is a MC-dependent phenomenon [162]. These important elements of 
a proper immune response are limited if MCs are persistently degranulating, due to the 
chronic inflammation exhibited by aged tissues [162]. Our recent studies revealed that 
activated MCs trigger NF-B-mediated reactions of mesenteric tissues in response to acute 
inflammation through release of histamine [172]. However, our studies also suggested that 
aging-associated persistent activation of MCs maintains a chronic histamine-dependent 
upregulation of NF-B signaling in aged perilymphatic mesenteric tissues which then 
limits NF-B activation in aged mesentery in response to acute inflammation [172]. 
Literature indicates that skin [174], bone marrow [175] and ocular [176, 177] MCs express 
various subtypes of HRs. However, considering the heterogeneity of MC receptor 
expression according to their niche specificity, it was still unknown whether mesenteric 




tested the hypothesis that mesenteric MCs not only release histamine but also maintain 
their activation through their expressed HRs in an autocrine manner, indicating the 
existence of a self-regulatory loop involving MCs, histamine, and HRs (i.e., a MC-
histamine autocrine loop).         
 The results of our study cumulatively confirm the presence of all of the elements 
forming a MC-histamine autocrine regulatory loop and its functional importance. Our 
current data indicate that mesenteric perilymphatic MCs drive an increase in 
synthesis/secretion of histamine in the mesentery in response to acute inflammatory 
stimulation. These MCs are the major source of mesenteric tissue histamine synthesis and 
release. HRs 1 and 2, but not HRs 3 and 4, are involved in the regulation of this response. 
HRs 1 and 2 differentially regulate acute inflammation-induced degranulation of 
mesenteric perilymphatic MCs and tissue histamine levels. HRs 1 and 2 in MCs regulate 
histamine synthesis and release by MCs. We confirmed that HRs 1 and 2 are present in the 
perilymphatic MCs and are able to effectively bind with extracellular histamine.  Receptor-
bound histamine is sufficient to induce MC activation and granule release in an H1R- and 
H2R-dependent manner.         
 The consequence of events forming the MC-histamine autocrine regulatory loop are 
shown in the proposed scheme presented in Fig. 18. We believe that the interaction of an 
acute inflammatory stimulus (e.g., LPS) with MCs (e.g., via Toll-like receptor 4 [TLR4]) 
stimulates TLR4-dependent NF-B phosphorylation [203, 204]. This further stimulates 
histamine synthesis by HDC and MC degranulation with subsequent release of histamine 
outside of MCs. This secreted histamine is able to bind in an autocrine manner with HRs 1 




in turn, maintains histamine synthesis by HDC [205], accumulation of histamine in MC 
granules and histamine release due to sustained MC activation. If this sustained MC 
activation, i.e. “basal activation of MCs” [5], is excessive, it will negatively affect immune 
cell function through diminished trafficking of MHCII+ cells and eosinophils towards 
lymphatic vessels [162], as well as alter lymphatic permeability and lymph transport 
function [5, 172, 206], therefore altering innate and adaptive immune responses. 
 Our present understanding of mechanisms of immune cell-lymphatic vessel 
interaction is far from complete. MCs are known to be key sensor and effector cells that 
are closely localized to lymphatic vessels [5]. Histamine is one of the major mediators 
secreted by MCs, which also has a vasoactive effect on lymphatic vessel contractile 
function [165, 169, 207-211]. At the same time, HRs and the histamine-synthesizing 
enzyme HDC are expressed in immune cell types, such as T and B cells [39, 212] and DCs 
[213, 214]. Moreover, histamine signaling influences maturation of DCs [214] and 
modulates the Th1 and Th2 type response via H1R- and H2R-modulated mechanisms [39, 
215]. Therefore, it is conceivable that histamine signaling plays a role as messenger for 
intercellular communication required for innate and adaptive immune responses. To 
demonstrate this further, we evaluated the importance of the elements of the MC-histamine 
autocrine regulatory loop (MH loop) for the acute inflammation-induced trafficking of the 
CD11b/c-positive cells towards MLVs. Time-dependent increases in infiltration of 
CD11b+ cells in mesenteric tissues by MLVs were reported previously as a typical 
response of mesenteric perilymphatic tissue compartments to LPS [193]. The results of our 
present study suggest that activation of mesenteric perilymphatic MCs triggers the 
trafficking of CD11b/c-positive cells to the adjacent MLVs in response to LPS-induced 
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acute inflammation. At the same time, inhibition of HRs 1 and 2 or MC stabilization 
abolishes this effect. Therefore, our present results support the conclusion that MC-
mediated histamine signaling is crucial for functional interactions between the CD11b/c+ 
cells and MLVs as well as for direct physical association and formation of “immune 
synapses” [183] between activated MCs and CD11b/c-positive cells. Such MC-CD11b/c-
positive connections are able to facilitate antigen transfer for T-cell activation [183]. 
Based on our present findings and previous observations reported in the literature, 
we believe that it is reasonable to propose the following sequence of events involving 
perilymphatic MCs (and the associated MH loop) in the regulation of lymphatic-directed 
trafficking of CD11b/c-positive cells. LPS-mediated activation of TLR4 initiates release of 
histamine by activated MCs located in high density by lymphatic vessels (and thereby 
activates the MH loop). Histamine secreted by MCs chemoattracts CD11b/c-positive cells 
towards MCs (and towards MLVs located nearby) and binds HRs expressed by the 
CD11b/c-positive cells. In addition, histamine, as well as LPS, facilitates NF-B-
dependent transcriptional upregulation of adhesion molecules such as VCAM1 on LECs. 
Surface expression of adhesion molecules on LECs will enable the binding of integrin 
molecules expressed by CD11b/c-positive cells recruited to MLVs by MCs, and will 
support migration of CD11b/c-positive cells through the lymphatic vessel wall. Schematic 
presentation of these events is shown in Fig. 12. At the same time, histamine binding with 
HRs 1 and 2 on MCs further supports continuous synthesis and release of histamine by 
MCs, thus maintaining the persistent (hours [193]) trafficking of CD11b/c-positive cells 
towards and through MLVs in a manner potentially independent of the initial LPS-TLR4 




interactions in this system may seriously diminish the ability of the MH loop to maintain 
the proper intensity of lymphotropic CD11b/c-positive cells trafficking.  
 Our finding of a functional MH regulatory loop leads to important basic and 
translational considerations. At this time, the functional importance of the MH loop under 
healthy conditions remains unclear. The threshold sensitivity of HRs in MCs, which are 
able to cause measurable changes in MCs induced by their own histamine synthesis and 
release, remains to be established through careful mechanistic studies. However, negative 
consequences of excessive and/or permanent activation of the MH loop could be severe, 
leading to altered functionality of immune cells [162, 172, 216], local tissue 
swelling/edema (due to the well-known effects of excessive histamine increasing vascular 
and lymphatic permeability [79, 217, 218] as well as altered lymphatic contractility and 
tone [97, 160, 169, 198, 209-211, 219-221]) and to acute and chronic allergies (recent 
reviews in [222, 223]). Hence, two translationally important questions remain unsolved: 
(1) What are the factors/conditions that promote transition of the MH loop function from a 
healthy (i.e. necessary) response mode to an excessive or/and chronic pathological (i.e. 
detrimental) response mode? (2) How does the MH loop and MLVs nearby influence each 
other and what is the functional importance of such interactions in health and disease? 
Answering these questions will require careful, time-consuming but necessary 
investigations of unknown [to a large degree] functional interactions between MCs and 
surrounding tissues. MLVs sense changes in their intralymphatic wall shear stress of 
different patterns and origin [137, 224, 225] and consequently adapt MLV phasic 
contractions and tone to the demands of a given moment in time [224, 226]. However, 
recent data demonstrated that a period of prolonged increase in lymph flow (which can be 
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related to the beginning stages of swelling in inflamed peripheral tissue compartments) is 
better managed by MLVs through their own histamine release [137]. This lymphatic-
derived histamine will diffuse out of MLVs towards adjacent MCs and by binding to HRs 
on MCs is able to trigger the MH loop. However, at this moment, the cumulative 
histamine-dependent effects of such a scenario, i.e. altered lymph flow, lymphatic 
permeability and immune cell trafficking, have not been carefully investigated. Factors 
driving a transition from a healthy to harmful response of the MH loop are completely 
unknown. The question of how the aging-associated increases of histamine production in 
MLVs [227] initiate and maintain persistent activation of the MH loop remains 
unanswered. The crucial importance of such studies is underscored by the fact that 
activated MCs, through release of histamine, trigger activation of NF-B-dependent 
signaling pathways (MC/histamine/NF-B axis [172]) that control transcription of DNA, 
cytokine production and cell survival. This phenomenon is found in almost all animal cell 
types and is involved in cellular responses to numerous stimuli/changes in the tissue 
microenvironment, including appearance of foreign antigens. These commonly accepted 
facts place MCs as a critical controlling sensor or trigger of many vital reactions in the 
body, with the MH loop serving as the first line in this cellular servo control system. Last 
but not least, from the perspective of proper functioning of the MC/histamine/NF-B axis 
and the MH loop, antihistamine treatment, which was initially designed to block harmful 
peripheral effects of histamine, also affects multiple organ systems through the HRs 
present in practically all body systems and through an unknown degree of alterations in the 
numerous histamine/NF-B-dependent signaling pathways. As an example, we have 
recently investigated negative effects of prolonged administration of desloratadine, [228]. 
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These alterations in the body include dysfunction of MLVS, excessive weight gain, 
increased density of abdominal subcutaneous fat and intracapsular brown fat, high blood 
triglycerides with an indication of their re-routing towards portal blood, high HDL, high 
fasting blood glucose with normal fasting and non-fasting insulin levels (insulin 
resistance), high liver/body weight ratio, and liver steatosis (fatty liver) [228]. Therapeutic 
MC stabilization [229-232] thus provides a potential future treatment modality by 
regulating MH loop without the off-target effects of antihistamines. 
In conclusion, our data collectively demonstrate that, after activation and 
degranulation by acute inflammation, MCs serve a role as a major source of extracellular 
histamine in perilymphatic mesenteric tissues. This histamine, released by MCs, is able to 
bind with HRs 1 and 2 on MCs and, as such, maintains or re-initiates further MC 
degranulation. This sequence of events forms the MH loop, the elements of which are 
crucially important for the acute inflammation-induced trafficking of CD11b/c-positive 
cells towards MLVs. Conclusively, our results place MCs in the position of being a critical 
cellular sensor or trigger of many vital reactions in the body, with the MH loop serving as 
a cellular servo control system. Maintaining a healthy functional status of the histamine-
mediated autocrine signaling in mesenteric perilymphatic MCs is a key factor in the proper 
course of an innate and adaptive immune response as well as maintenance of body 
homeostasis in general.
3. HISTAMINE RECEPTOR 2 NUCLEAR LOCALIZATION
3.1. Introduction 
Histamine is synthesized and present in a number of mammalian tissues and exerts 
its function through modulation of its four G protein coupled receptor (GPCR) subtypes, 
namely H1R-4. H2R is well known for stimulation of gastric acid secretion however 
expression of H2R is also found in the cardiovascular system [233], different cell types of 
the immune system as well as in the brain [56]. Interestingly recent studies report ability of 
H2R to antagonize certain effects of H1R such as relaxation of smooth muscle cells, 
inhibition of both Th1 and Th2 type of reactions [39] and differentially affecting MC 
degranulation. H2R belongs to the GPCR subfamily A17 and is coupled with its signaling 
partner G alpha S whereas other HRs belong to the GPCR A18 subfamily and signal 
through G alpha q. H2R shows a unique sequence similarity with the beta 1 adrenergic 
receptor and both belong to the same GPCR family, which has recently been shown to 
have a nuclear localization in cardiomyocytes [234].   
The precise mechanism by which H2R exhibits such antagonistic effects remains 
unclear. An emerging number of studies show that some GPCRs previously presumed to 
be expressed solely in plasma membranes can also function as nuclear receptors. These 
include prostaglandin E2 receptor [235] oxytocin receptors [236], CysLT1 receptor [237], 
sphingosine 1 phosphate receptor subtype 1 [238], and chemokine receptor CCR2 [239]. 
Our recent finding in Fig. 9 and 14  2.7.A2 show H2R also exhibits consistent nuclear 
localization, which led us to investigate the role of H2R in the nucleus. 
Here we have evaluated nuclear localization of H2R in human and rat primary cell 
lines using immunofluorescence staining along with whole organ tissue samples such as rat 
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liver and mesenteric perilymphatic segments. Further, we have shown co-localization of 
H2R and G alpha S and H2R with the nuclear envelope marker Lamin A. We have 
examined the role of histamine-dependent nuclear translocation of H2R at various time 
points and the effect of pharmacological blockade of H2R’s nuclear translocation. Both 
immunofluorescence staining and fluorescently labelled histamine demonstrate activation 
through histamine binding is necessary for further translocation of H2R into the nucleus. 
These findings strongly suggest an unrecognized role of H2R as a potential nuclear 
receptor. Further experiments are warranted to reinforce this novel finding such as 
cytosolic and nuclear fractionation of cells expressing H2R in response to histamine, gain 
and loss of function of H2R using GFP- or YFP-labeled constructs, and documenting 
transcriptional upregulation of specific genes that are mediated by H2R-depending 
signaling cascades.   
3.2. Material and Methods 
3.2.1. Surgical isolation of mesenteric perilymphatic tissue for immunofluorescence 
staining  
Surgical procedures and perilymphatic segment isolation were performed as 
described in 2.2.2. All animal procedures for the current studies were reviewed and 
approved by the Texas A&M University Institutional Animal Care and Use Committee. 
Briefly, rats were euthanized by overdose of isoflurane followed by thoracotomy. 
Immediately post mortem, the sternum and half of the adjacent ribs were excised and the 
inferior vena cava was cut to drain blood. The abdominal cavity was opened by midline 
abdominal incision, the two ends of the gut included in the area to be excised were sutured 
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before excision to avoid fecal contamination of the preparation, and the root of the 
mesentery was clamped to minimize further bleeding. The excised gut with attached 
mesentery was rinsed three times in 1x PBS. For perilymphatic tissue dissection, the gut 
was pinned down in a Sylgard
®
-coated 10-mm Petri dish and submersed in cold
physiological salt solution with the pH adjusted to 7.36. The whole mesentery from an 
individual animal was rapidly excised and, using a dissecting microscope, was separated 
into segments that included MLVs and perilymphatic tissues, but did not include large 
segmental mesenteric arteries or veins. As MCs are sensitive to mechanical stress and 
stretch, special care was taken to ensure minimal manipulation during tissue dissection. 
Immunofluoresence staining for H2R and G alpha S (ab 235956) was performed as 
described in the section 2.2.5. 
3.2.2. Cell culture and immunofluorescence for H2R and G alpha S localization 
Human dermal LECs (HDLECs), human intrahepatic biliary epithelial cells 
(HIBECs) and murine cholangiocyte cell lines were grown in Nunc 35-mm glass bottom 
dishes with appropriate medium and cultured as described previously [240-242].  After 
reaching 80-90% confluence, cells were fixed in PFA (1% w/v in PBS, pH 7.4) for 15 
minutes; washed 3 times with 1X PBS, and blocked with 5% goat serum (in PBS 
containing 0.1% Triton X-100) for 60 min at room temperature. For HDLECs Prox1 was 
used as a cell-specific marker and for HIBECs and murine cholangiocytes CK-19 was used 
as a cell-specific marker. Cells were incubated with primary antibodies (1:100 dilution) 
overnight at 4ºC followed by washing (3 times with PBS), subsequent incubation with 




 Live reagent for nuclear staining. Images were acquired using
the same acquisition settings for all slides (here and below) on an Olympus Fluoview 300 
confocal microscope with a 40x water objective with 1.15 numerical aperture, step size of 
0.5 m and 488, 647 and 360 nm laser lines. 
For evaluation of H2R and G alpha S co-localization, staining of H2R was 
performed using Alexa Fluor 647 goat anti-rabbit H+L secondary antibody and for G alpha 
S Alexa Fluor 488-goat anti mouse secondary antibody was used (both at 1:200 dilution). 
3.2.3. Evaluation of localization of H2R by immunohistochemistry in whole tissue 
segments 
Isolated rat perilymphatic tissue segments and liver sections (4-µm thick) were 
evaluated for expression of H2R by immunohistochemistry [241, 243]. Tissue sections 
were incubated overnight at 4°C with H2R antibody (1:50), washed with PBS, 
subsequently incubated for 20 min with a secondary biotinylated antibody at room 
temperature (Dako Cytomation LSAB Plus System-HRP, Glostrup, Denmark), and further 
incubated with Dako ABC for 20 min and finally developed with 3–3 diaminobenzidine 
(Dako Cytomation Liquid DAB Plus Substrate Chromogen System). Sections were imaged 
with a BX-51 light microscope (Olympus, Tokyo, Japan) using a video camera (Spot 
Insight; Diagnostic Instrument, Sterling Heights, MI) and processed with an image analysis 




3.2.4. BLAST analysis 
The amino acid sequence of H2R was compared with previously described nuclear 
receptors to find sequence similarity using basic local alignment search tool (BLAST). The 
NCBI-provided BLAST for protein bioinformatics tool was used where FASTA sequences 
for alignment for two proteins at a time was utilized. Nuclear receptors such as estrogen 
receptor alpha (ERα), thyroid hormone receptor alpha (TRα) [244], beta 1 adrenergic 
receptor [234] along with H1R(A18), which belongs in a different GPCR subfamily than 
H2R (A17). For comparison between H2R and other proteins, sequence identity, query 
cover and total score were compared [245].  
 
3.2.5. Time-dependent nuclear translocation of H2R in the presence of histamine 
HDLECs were grown in Nunc 35-mm glass bottom dishes with appropriate culture 
medium and grown to 80-90% confluence. Cells were washed with PBS and thereafter 
treated with a final concentration of 10µM histamine in serum-free medium for 30, 60 and 
90 minutes along with an untreated control. For H2R blockade, cells were washed and 
treated with 100 µM cimetidine for 1 hour and subsequently treated with 100 µM 
cimetidine and histamine for 60 min. After treatment, cells were fixed and immunostained 
for H2R as well as Prox1 and imaging was done as described in section 3.2.2. Staining 
with DAPI gives the periphery of the nucleus. Using image J MFI of the area of nucleus as 
well as the area of cytoplasm excluding nucleus were determined. Further percentage was 
calculated using the formulae (cytoplasmic H2R MFI / nuclear H2R MFI)*100 for at least 





3.2.6. Fluorescently labeled histamine binding assay 
HDLECs were grown in Nunc 35-mm glass bottom dishes with appropriate culture 
medium and grown to 80-90% confluence. Cells were washed with PBS and thereafter 
treated with 100 µM cimetidine or left untreated in serum-free medium for 60 min. Cells 
were then incubated with 10µM fluorescently-tagged histamine (EverFluor FL histamine) 
for 60 min. Proper caution was taken to avoid direct exposure to light during this and the 
following procedures. After 60 min of incubation, unbound dyes were rinsed by washing 3 
times for 10 min each in PBS at 4°C and subsequently cells were fixed and washed with 
PBS 1 time and mounted with NucBlue
TM
 Live reagent for nuclear staining. Image 
acquisition was done using a 40x water immersion objective on an Olympus Fluoview 300 
confocal microscope under appropriate excitation/emission wavelengths. The image 
analysis approach was similar to that described in 3.2.4. 
 
3.3. Results  
3.3.1. Nuclear localization of H2R in whole tissue and in different cultured cell types 
The previous observation of H2R localization in perilymphatic tissues suggested 
that H2R co-localizes with DAPI in MCs (Fig 19 A.1) as well as other H2R-expressing 
cells. This observation led us to investigate the nuclear expression pattern of H2R in 
primary cultured cell lines such as rat cholangiocytes, HDLECs and HIBECs. Rat 
cholangiocytes had previously been shown to express H2R [246]. Using isolated cultured 
primary rat cholangiocytes, which express CK19, we show H2R nuclear localization along 




with HDLECs (expressing Prox-1) and HIBECs (expressing CK-19) shown in Fig. 19 A.3 
and Fig. 19 A.4, respectively.      
 
Figure 19.  Nuclear localization of H2R shown in different cell types. A.1 Rat 
perilymphatic MCs, A.2 Rat cholangiocytes, A.3 HDLECs, and A.4 HIBECs express H2R 




Further, immunohistochemical staining for H2R in rat perilymphatic tissues (Fig. 




A.2). Altogether these results suggest a consistent nuclear localization pattern of H2R 
across different cell types from human as well as rat. 
 
 
Figure 20. Whole tissue immunohistochemical staining  of H2R showing  nuclear 
localization.  A.1 Immunohistochemical staining of H2R in perilymphatic tissue segments 
(inset shows localization of H2R). A.2 Immunohistochemical staining of H2R in liver 




3.3.2. Nuclear localization of the H2R signaling partner G alpha S in cultured cells 
and in whole tissue 
Activation of H2R-mediated signaling involves activation of the downstream signaling 
partner G alpha S [247].  Therefore, to assess whether G alpha S is also expressed in the 
nucleus, immunofluorescence staining was done in HDLEC and HIBEC human cell lines 




of Fig. 21.A.1, A.2, A.3 consistently shows a distinct nuclear localization of G alpha S. 
This finding is in agreement with a previous finding of G proteins localized in nuclear 
membranes and in intra-nuclear structures in adult cardio-myocytes [234].   
 
 
Figure 21. Nuclear localization of G alpha S in different cell types. HIBECs (A.1) and 
HDLECs (A.2) expressing respective markers Prox-1 and CK19 (in green) with red 
channel showing localization of G alpha S. Co-localization of H2R and nucleus (stained 











3.3.3. Co-localization of H2R with G alpha S and Lamin A as well as BLAST analysis 
suggests H2R as potential nuclear receptor 
Immunofluorescence staining results further led us to investigate nuclear co-
localization of H2R and G alpha S in HDLECs. Fig. 22. A.2 shows G alpha S in green in 
the left panel, H2R in red in the middle panel, and colocalization of both with DAPI in the 
right panel. To further support this finding of H2R nuclear localization, rat perilymphatic 
tissues were co-stained for the nuclear envelope marker Lamin A (Fig. 22 A.1) and a 
similar observation of H2R nuclear co-localization was made.  
 
 
Figure 22. Co-localization study of H2R with G alpha S and Lamin A.  Rat 
perilymphatic tissue (A.1) and HDLECs (A.2) are shown. Rat perilymphatic tissue 
expressing Lamin A in the green channel and H2R in red channel exhibit clear localization 
of H2R inside of the nuclear envelope. When merged with DAPI staining (A.2), G alpha s 






Several hormone receptors, such as beta 1 adrenergic receptor, estrogen receptor 
alpha, thyroid receptor alpha, are GPCRs and have been shown to be expressed in the 
nucleus, to bind with respective chaperones and hormone response elements and 
participate in transcription of associated genes contributing to several developmental 
programs as well as in regulation of physiological homeostasis. However, due to 
unavailability of the three-dimensional crystal structure of H2R, which limits predictability 
of its DNA binding domain, we evaluated sequence similarity with other known nuclear 
receptors using a bioinformatic approach, i.e, BLAST. H1R was also compared in this 
analysis as H1R and H2R both belong to same rhodopsin-like GPCR superfamily (A18). 
The BLAST result suggests (Fig. 23) that query coverage and identity is significantly less 
when compared with H2R vs. thyroid receptor alpha or estrogen receptor alpha. As a 
positive control, the thyroid receptor alpha and estrogen receptor alpha were compared and 
showed significant query coverage (74%) and identity (24%). When compared with H1R 
and H2R, even though they belong to a different subfamily, there was significant identity 
and query coverage, suggesting that they both may have some similar domain structure. 
However, interestingly, beta adrenergic receptor 1, which has recently been described as a 
nuclear receptor and present in the same GPCR subfamily as H2R (A18), showed 
significant query coverage (69%) and identity (34%) and exhibited a higher total score of 
228 (Fig. 23). These values suggest the possibility of H2R as a potential GPCR that is able 
to translocate into the nucleus and bind DNA, functioning as a nuclear receptor. 
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Figure 23. BLAST analysis of H2R 
3.3.4. Histamine-dependent nuclear translocation of H2R 
To elucidate H2R as a potential nuclear receptor, HDLECs were treated with 
histamine for 0, 30, 60 and 90 min. Immunofluorescence staining for H2R was done to 
study histamine-dependent nuclear translocation at those time points. The results suggest 
that in untreated cells (i.e., the unstimulated condition) H2R appears to be present in the 
cytoplasm (Fig. 24 A.1). However, after 30 min (Fig. 24 A.2) of treatment with histamine, 
H2R localizes to the nucleus. This translocation pattern of H2R towards the nucleus 




shows 90 min of treatment). The quantification of time-dependent nuclear translocation of 
H2R is shown in the right panel as a percentage of cytoplasmic to nuclear MFI and 
demonstrates the highest MFI of H2R in the nucleus of HDLECs at the 60-min time point. 
 
   
 
Figure 24. Histamine-dependent nuclear translocation of H2R.  Left panels show 
merge of Prox1, H2R and DAPI staining. Middle panels show H2R and right panels show 
the zoomed view of a single cell. A.1 represents H2R localization of unstimulated cells; 
A.2 30 min, A.3 60 min, and A4 90 min of histamine treatment and associated H2R 
nuclear localization. B. Quantification of the ratio of cytoplsmic to H2R MFI in different 
time points. 
 
To further assess whether histamine-dependent H2R activation is necessary for this 
translocation process, HDLECs were pretreated with a pharmacological blocker of H2R 




Fig. 25 A.2 suggest histamine-dependent activation of H2R mediates H2R translocation to 
the nucleus in a 60-min time frame; however, when H2R is inhibited by an antagonist, its 
nuclear translocation is significantly reduced. Quantification of H2R cytoplasmic:nuclear 
MFI, with or without  the H2R blocker, is shown in the graph in the far right panel. This 
data supports the requirement of binding of histamine to H2R for H2R nuclear 
translocation, as pre-treatment with the H2R antagonist significently attenuated 
cytoplasmic:nuclear MFI of H2R in the  nucleaus. 
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Figure 25. Inhibition of H2R significantly attenuates histamine-dependent nuclear 
translocation. Upper left panel in A.1 shows the H2R nuclear translocation in response to 
60 min of histamine treatment. Upper left panel of A.2 shows that H2R pharmacological 
blockade significantly attenuates this histamine-dependent nuclear translocation effect. 
Insets show the corresponding magnified images of H2R translocation under the different 
treatments. B. Quantification of MFI in response to histamine and  histamine with H2B 
treatment. 
3.3.5. Pharmacological blockade of H2R attenuates nuclear localization of 
fluorescently labelled histamine 
To further explore histamine-dependent nuclear translocation of H2R, fluorescently 
tagged histamine (Flu-His) molecule was used.  Fig. 26 A.1 shows treatment of HDLECs 
with the Flu-His molecule resulted in significant fluorescence signal from the nucleus. 
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However, when cells are treated with an H2R antagonist, the H2R MFI in the nucleus was 
significantly diminished (Fig. 26 A.2). The quantification of the signal is shown in the 
right most panel. This result shows the ligand-dependent nuclear translocation of H2R. 
Figure 26: Inhibition of H2R attenuates nuclear translocation. Left panels show signal 
from the Flu-His molecule inside HDLECs, the middle panels show signal from DAPI 
staining of the nucleus, and the right panels show colocalization of the Flu-His and DAPI 
staining without (A.1) and with (A.2) pretreatment with an H2R blocker.   
3.4. Discussion 
Histamine is a ubiquitously expressed biogenic amine synthesized by a number of 
cells in the immune as well as vascular system. Activation and modulation of its widely 
expressed receptors (1-4) is able to regulate several essential cellular functions as well as 
inflammatory reactions. However, present understanding of the mechanistic basis of the 
distinctly antagonistic effects of H2R and H1R is still unknown. For example, previous 




response whereas activation of H2R can negatively regulate both Th1 and Th2 type 
responses and associated T cell-derived cytokines.  
Histamine receptor subtypes 1-4 belong to different subfamilies of GPCRs. H1, H3 
and H4 receptors belong to the A18 rhodopsin subfamily of GPCRs whereas H2R belongs 
to the A17 subfamily. Furthermore, the signaling mechanism differs considerably between 
H1R and H2R. Activation of H1R couples with G alpha q in a phospholipase C-dependent 
manner, whereas the H2R-mediated signaling process engages G alpha s an a protein 
kinase C-dependent manner [56]. Many GPCRs, such as prostaglandin E2 [248] and beta 1 
adrenergic receptor [234], partner with G alpha S and also co-localize with G alpha S 
present in the nucleus.  
Our current observations on H2R are consistent with the growing evidence of 
GPCRs localizing in the nucleus and exhibiting functional relevance as nuclear receptors. 
We showed in cells from different tissue types along with human and rat cell lines that 
H2R shows a consistent nuclear localization pattern and co-localizes with its binding 
partner G alpha S in the nucleus. Further, we explored the kinetics of histamine-dependent 
nuclear translocation of H2R. We showed that in the presence of an H2R antagonist this 
translocation pattern to the nucleus is significantly inhibited. This also suggests that 
binding of H2R with its ligand histamine is necessary for its translocation mechanism.  
Present data raise several questions. For example, if H2R serves as a nuclear 
receptor and interacts with transcription machinery, then what are the target genes that are 
associated with H2R-mediated transcriptional regulation? A putative mechanism for 




gain of function and loss of function constructs in a heterologous expression system to 
elucidate the role of H2R as a nuclear receptor. 
   
 
Figure 27. Putative H2R nuclear localization mechanism. In its inactive form, H2R may 
be bound with heat shock proteins (HSP). However, binding with histamine can induce a 
conformational change in the H2R structure leading to release of H2R from this H2R-HSP 
complex and subsequent translocation to the nucleus. In the nucleus, H2R along with other 




Based on the present data it is reasonable to conclude that the presence and 
localization of H2R in the nucleus suggests that histamine, as a widely synthesized 
molecule in several cell and tissue types having one of four of its cognate receptors, can 
differentially activate cellular signaling networks. H2R as a nuclear receptor may directly 




can specifically drive the expression and translocation of H2R, what specific genes are 
associated with H2R-mediated transcriptional regulation, and what other regulatory 
molecules (such as transcriptional activators and repressors) are involved in this nuclear 





4. CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1. Conclusions and future direction of research into histamine-mediated autocrine 
signaling in mesenteric perilymphatic MCs  
Previously, we demonstrated that in addition to NO, histamine serves as a relaxing 
factor for lymphatic vessel pumping function. Proper relaxation of the lymphangion is 
crucial for steady state maintenance of ejection fraction of lymph and lymphatic vessel 
tone. In addition to the lymphatic vessel-derived histamine, which we have recently shown, 
in this study we show that perilymphatic tissue MCs adjacent to the collecting lymphatic 
vessels are the major contributor of tissue histamine. However, it was unknown how these 
MCs regulate their secretion of histamine in perilymphatic tissue. To explore, we tested the 
hypothesis that perilymphatic mesenteric MCs express HRs that bind and respond to the 
histamine that they release. Under inflammatory stimulation by LPS, we measured 
histamine in mesenteric perilymphatic tissues, evaluated expression of histidine 
decarboxylase, the degree of MC degranulation, assessed the functional status of HRs in 
MCs, and evaluated the ability of histamine itself to induce MC activation. Finally, we 
evaluated the significance of MCs and H1R and H2R for MLV-directed trafficking of 
CD11b/c-positive cells during LPS-mediated acute tissue inflammation. Our data indicate 
the existence of a functionally active MC-histamine autocrine regulatory loop, the elements 
of which are crucially important for acute inflammation-induced trafficking of the 
CD11b/c-positive cells towards MLVs. Our data also suggests that this MC-histamine loop 




 In chapter 2, we dissected individual components of the autocrine signaling module 
of MCs in the mesenteric perilymphatic niche and established a functional relationship of 
this regulation in lymphatic immuno-physiology. However, several outstanding questions 
still remain. For example, what is the putative molecular mechanism for how NF-kB 
influences HDC expression in MCs in response to LPS? One plausible explanation would 
be that NF-kB can serve as a possible transcription factor of HDC. It is still unknown 
whether inhibition of NF-kB phosphorylation can rescue acute inflammation-dependent 
MC degranulation. Thus, what is the molecular basis of such distinct yet differential 
granule release patterns of MCs in response to H1 and H2 antagonists in acute 
inflammation? What are the intracellular signaling networks modulated by different HRs in 
this process?  Some potential mechanisms can be tested, such as engagement of V-SNARE 
and T-SNARE proteins, histamine receptor-dependent intracellular calcium mobilization 
modulated by calcium ATPases such as sarco/endoplasmic reticulum Ca+2 ATPases 
(SERCA) and so forth. Lastly, in this study, we have shown histamine signaling plays a 
crucial role in MLV-directed chemotactic migration of antigen presenting cells. However, 
observations from previous studies and the current study also imply that histamine can 
modulate expression of adhesion molecules in LECs of the adjacent lymphatic vessels. 
However, histamine-mediated modulation of adhesion molecule expression in LECs is an 
area where much is still unknown. 
4.2. Conclusions and future direction of research into histamine receptor 2 nuclear 
localization and role as a nuclear receptor 
We demonstrated the nuclear localization of H2R in different tissue types and 




to further investigate the possible mechanism of such localization of H2R. We elucidated 
the kinetics of histamine-dependent nuclear translocation of H2R and showed that blocking 
histamine binding with H2R significantly attenuates this translocation event. Using 
fluorescently labelled histamine, we further studied receptor-ligand interaction with or 
without the presence of an H2R antagonist. Together our results suggest that H2R 
receptor-ligand complex formation is necessary for its nuclear translocation, which is a 
characteristic of type 1 nuclear receptor signaling.  
In the field of receptor biology, a longstanding question is whether a ligand, which 
has more than one cognate receptor subtype, simultaneously expressed in a particular cell 
type, how can modulate expression of specific receptor subtypes and activation of 
downstream signaling cascade? Is the binding of the ligand with its receptors random or 
stochastic? This further emphasizes two questions: (1) Non-repetitive functionality of 
cognate receptors to maintain their evolutionary fitness and (2) A possible preferential 
stochastic ratio of a certain subtype in a certain point of time over others potentially 
governed by the intrinsic and extrinsic environment of the cell [249, 250]. For example, 
histamine has four receptor subtypes. MCs express both H1R and H2R. H1R and H2R 
mediate different downstream signaling cascades; however activation of both of these 
receptors is dependent upon binding with its ligand histamine. Therefore, the question is: If 
both receptors are simultaneously expressed, which receptors are going to bind with 
histamine first? How can this binding activity be regulated? These unresolved questions 
reinforce the need for deeper understanding of the basic principle of gene expression 
programs. Our present finding of H2R as a potential nuclear receptor at least in some 




receptor subtypes in a given cell type. It is plausible to argue that the presence of H2R in 
the nucleus provides an explanation for why histamine, as a widely synthesized molecule 
in several cell and tissue types, when synthesized locally, can bring about H2R-dependent 
modulation of gene transcription, enabling the cell to respond preferentially to that receptor 
over other HRs. However, other questions remain unresolved: (1) What are the genes are 
affected by H2R transcriptional output (activation/repression)? (2) What is the specific 
responsive element of H2R? (3) As the crystal structure is not resolved, what is the DNA-
binding domain of H2R? (4) Are specific heat shock proteins associated with H2R, 
forming an inactive form while present in the cytosol? Overall, the concept of H2R as 
nuclear receptor raises a number of unresolved questions that not only can influence the 
histamine signaling field but also suggest a deeper physiological implication in the 
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